var docs;if (!docs) docs =[]; docs["104"]={"10400":"<p><b>Title</b> Estriol (Topical) / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C:Monitor therapy</p> \n<p><b>Summary</b> Ritonavir may decrease the serum concentration of Estriol (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased estriol effects (eg, decreased symptom relief, changes in uterine bleeding profile) if combined with ritonavir.</p> \n<p><b>Discussion</b> Prescribing information for estriol states that no interactions between estriol and other medications have been reported in clinical practice.<sup>1,2,3</sup> However, concomitant use of other estrogen products, particularly oral contraceptives, with ritonavir has resulted in increased estrogen metabolism and decreased efficacy.<sup>1,2,3</sup> Although data are limited, similar interactions between estriol and ritonavir may occur.<sup>1,2,3</sup> Monitor patients for decreased estriol effects if these agents are combined.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ovestin [summary of product characteristics] Dublin, Ireland: Aspen Pharma Trading Limited; September 2014.</p>\n<p>2. Ovestin Ovula [prescibing information]. New South Wales, Australia: Aspen Pharmacare. Available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2015-PI-02993-1&amp;d=2016042816114622483; Accessed December 2015.</p>\n<p>3. Ovestin [product information] New South Wales, Australia: Aspen Pharmacare. Available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2014-PI-02257-1&amp;d=2016042816114622483; Accessed July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10401":"<p><b>Title</b> Lenograstim / Antineoplastic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antineoplastic Agents may diminish the therapeutic effect of Lenograstim. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.</p>\n<div>\n <p><b>Antineoplastic Agents Interacting Members</b> Altretamine, Amsacrine, AzaCITIDine, Belotecan, Bendamustine, Bleomycin, Busulfan, Cabazitaxel, Capecitabine, CARBOplatin, Carmustine, Chlorambucil, CISplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine (Conventional), Dacarbazine, DACTINomycin, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Decitabine, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), EpiRUBicin, EriBULin, Estramustine, Etoposide, Etoposide Phosphate, Floxuridine, Fludarabine, Fluorouracil (Systemic), Fotemustine, Gemcitabine, Hydroxyurea, IDArubicin, Ifosfamide, Irinotecan (Conventional), Irinotecan (Liposomal), Ixabepilone, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, Methotrexate, MitoMYcin (Systemic), MitoXANTRONE, Nelarabine, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), PEMEtrexed, Pentostatin, Pixantrone, PRALAtrexate, Procarbazine, Raltitrexed, Streptozocin, Tegafur, Temozolomide, Teniposide, Thioguanine, Thiotepa, Topotecan, Trabectedin, Treosulfan, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine</p>\n</div> \n<p><b>Discussion</b> Lenograstim product labeling states that the safety and efficacy of lenograstim administered on the same day as myelosuppressive cytotoxic chemotherapy has not been established.<sup>1,2</sup> Since rapidly dividing myeloid cells (ie, those stimulated by use of lenograstim) are particularly sensitive to the effects of myelosuppressive cytotoxic chemotherapy, the use of lenograstim should not precede or overlap the administration of cytotoxic chemotherapy.<sup>1,2</sup> It is recommended that lenograstim should start at least 24 hours after the completion of chemotherapy.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Granocyte (lenograstim) [summary of product characteristics]. Turnham Green, London, UK: Chugai Pharma UK Limited; April 2015.</p>\n<p>2. Granocyte (lenograstim) [summary of product characteristics]. Melbourne, Australia: Hospira Australia Pty Ltd; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10402":"<p><b>Title</b> Gestrinone / Fosphenytoin-Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin-Phenytoin may decrease the serum concentration of Gestrinone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of reduced gestrinone effectiveness when used together with an enzyme-inducing antiepileptic drug such as phenytoin or fosphenytoin.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> Specific data concerning this combination are not available, but the gestrinone labeling states that enzyme-inducing antiepileptic drugs may accelerate gestrinone metabolism, which would be expected to result in diminished gestrinone concentrations and effects.<sup>1</sup><br><br>These drugs are predicted to interact based on the ability of enzyme-inducing drugs such as phenytoin to increase enzyme-mediated metabolism of gestrinone. The specific enzyme most responsible for gestrinone metabolism is not clear, but phenytoin, like most enzyme-inducing drugs, is capable of inducing many of the most common drug metabolizing enzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dimetriose (gestrinone) [summary of product characteristics]. Lane Cove, New South Wales, Australia: Aventis Pharma Pty Ltd; October 1994.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10403":"<p><b>Title</b> Gestrinone / PHENobarbital</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> PHENobarbital may decrease the serum concentration of Gestrinone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of reduced gestrinone effectiveness when used together with an enzyme-inducing antiepileptic drug such as phenobarbital.</p> \n<p><b>Discussion</b> Specific data concerning this combination are not available, but the gestrinone labeling states that enzyme-inducing antiepileptic drugs may accelerate gestrinone metabolism, which would be expected to result in diminished gestrinone concentrations and effects.<sup>1</sup><br><br>These drugs are predicted to interact based on the ability of enzyme-inducing drugs such as phenobarbital to increase enzyme-mediated metabolism of gestrinone. The specific enzyme most responsible for gestrinone metabolism is not clear, but phenobarbital, like most enzyme-inducing drugs, is capable of inducing many of the most common drug metabolizing enzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dimetriose (gestrinone) [summary of product characteristics]. Lane Cove, New South Wales, Australia: Aventis Pharma Pty Ltd; October 1994.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10404":"<p><b>Title</b> Gestrinone / Primidone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Primidone may decrease the serum concentration of Gestrinone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of reduced gestrinone effectiveness when used together with an enzyme-inducing antiepileptic drug such as primidone.</p> \n<p><b>Discussion</b> Specific data concerning this combination are not available, but the gestrinone labeling states that enzyme-inducing antiepileptic drugs may accelerate gestrinone metabolism, which would be expected to result in diminished gestrinone concentrations and effects.<sup>1</sup><br><br>These drugs are predicted to interact based on the ability of enzyme-inducing drugs such as primidone to increase enzyme-mediated metabolism of gestrinone. The specific enzyme most responsible for gestrinone metabolism is not clear, but primidone, like most enzyme-inducing drugs, is capable of inducing many of the most common drug metabolizing enzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dimetriose (gestrinone) [summary of product characteristics]. Lane Cove, New South Wales, Australia: Aventis Pharma Pty Ltd; October 1994.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10405":"<p><b>Title</b> Gestrinone / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Gestrinone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of reduced gestrinone effectiveness when used together with an enzyme-inducing antiepileptic drug such as carbamazepine.</p> \n<p><b>Discussion</b> Specific data concerning this combination are not available, but the gestrinone labeling states that enzyme-inducing antiepileptic drugs may accelerate gestrinone metabolism, which would be expected to result in diminished gestrinone concentrations and effects.<sup>1</sup><br><br>These drugs are predicted to interact based on the ability of enzyme-inducing drugs such as carbamazepine to increase enzyme-mediated metabolism of gestrinone. The specific enzyme most responsible for gestrinone metabolism is not clear, but carbamazepine, like most enzyme-inducing drugs, is capable of inducing many of the most common drug metabolizing enzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dimetriose (gestrinone) [summary of product characteristics]. Lane Cove, New South Wales, Australia: Aventis Pharma Pty Ltd; October 1994.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10406":"<p><b>Title</b> Gestrinone / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Gestrinone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of reduced gestrinone effectiveness when used together with rifampin.</p> \n<p><b>Discussion</b> Specific data concerning this combination are not available, but the gestrinone labeling states that rifampin may accelerate gestrinone metabolism, which would be expected to result in diminished gestrinone concentrations and effects.<sup>1</sup><br><br>These drugs are predicted to interact based on the ability of rifampin to increase the metabolism of gestrinone. The specific enzyme most responsible for gestrinone metabolism is not clear, but rifampin, like most enzyme-inducing drugs, is capable of inducing many of the most common drug metabolizing enzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dimetriose (gestrinone) [summary of product characteristics]. Lane Cove, New South Wales, Australia: Aventis Pharma Pty Ltd; October 1994.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10407":"<p><b>Title</b> Bleomycin / Lenograstim</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lenograstim may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased. Bleomycin may diminish the therapeutic effect of Lenograstim. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of lenograstim 24 hours before until 24 hours after the completion of bleomycin infusion. Additionally, monitor patients more closely for signs/symptoms of bleomycin pulmonary toxicity when used with lenograstim (G-CSF). Be aware that the use of such a combination may increase the risk for potentially severe pulmonary toxicity.</p> \n<p><b>Discussion</b> Lenograstim product labeling states that the safety and efficacy of lenograstim administered on the same day as myelosuppressive cytotoxic chemotherapy, such as bleomyin, has not been established.<sup>1,2</sup> Since rapidly dividing myeloid cells (ie, those stimulated by use of lenograstim) are particularly sensitive to the effects of myelosuppressive cytotoxic chemotherapy, the use of lenograstim should not precede or overlap the administration of cytotoxic chemotherapy.<sup>1,2</sup> It is recommended that lenograstim should start at least 24 hours after the completion of chemotherapy.<sup>1,2</sup><br><br>In addition to reduced lenograstim efficacy, the combined use of bleomycin and lenograstim may increase the risk for pulmonary toxicity. According to one report, evidence of possible bleomycin-associated pulmonary toxicity was observed in 4 of 5 patients receiving G-CSF in combination with the ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy regimen.<sup>3</sup> The authors considered this noteworthy due to the unusually high rate of toxicity, particularly since the patients with evidence of toxicity received more than 5-fold lower doses of bleomycin that that normally associated with risk of pulmonary toxicity. Another case report describes a patient with rapidly-developing and fatal pulmonary toxicity attributed to concurrent use of bleomycin and G-CSF.<sup>4</sup><br><br>A retrospective analysis of 141 bleomycin-treated patients, 25 (18%) of whom experience bleomycin-associated pulmonary toxicity, similarly identified concurrent G-CSF use as a potential risk factor for pulmonary toxicity.<sup>5</sup> Among patients with pulmonary toxicity, 76% received G-CSF vs. only 47% of bleomycin recipients without pulmonary toxicity (p = 0.014). Increased age and use of the ABVD chemotherapy regimen were also identified as potential risk factors in the univariate analysis; due to the relatively small number of cases available, no multivariate analyses were reported. Several animal studies also support the association between G-CSF (or GM-CSF) use and a greater risk for bleomycin pulmonary toxicity.<sup>6,7,8</sup><br><br>In contrast, one comparison of the rates of bleomycin toxicity reported a similar rate of toxicity among both 29 patients treated with bleomycin plus G-CSF and 57 patients treated with bleomycin, etoposide, and cisplatin (but no G-CSF) (34% vs. 33%, respectively).<sup>9</sup><br><br>Additional data from studies designed to specifically address this issue are needed in order to definitively characterize this purported interaction, but the data currently available seem sufficient to justify greater caution when considering the concurrent use of bleomycin with either G-CSF or GM-CSF.<br><br>The exact mechanism(s) by which this combination may increase the risk of pulmonary toxicity is not certain, but an increase in granulocyte function and/or number due to G-CSF/GM-CSF administration is suspected.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Granocyte (lenograstim) [summary of product characteristics]. Turnham Green, London, UK: Chugai Pharma UK Limited; April 2015.</p>\n<p>2. Granocyte (lenograstim) [summary of product characteristics]. Melbourne, Australia: Hospira Australia Pty Ltd; April 2016.</p>\n<p>3. Matthews JH. Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin’s disease: possible synergy. <i>Lancet</i>. 1993;342(8877):988. [PMID: 7692199]</p>\n<p>4. Dirix LY, Schrijvers D, Druwe P, Van den Brande J, Verhoeven D, Van Oosterom AT. Pulmonary toxicity and bleomycin. <i>Lancet</i>. 1994;344(8914):56. [PMID: 7516990]</p>\n<p>5. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. <i>J Clin Oncol</i>. 2005;23(30):7614-7620. [PMID: 16186594]</p>\n<p>6. Adachi K, Suzuki M, Sugimoto T, Uetsuka K, Nakamaya H, Doi K. Effects of granulocyte colony-stimulating factor on the kinetics of inflammatory cells in the peripheral blood and pulmonary lesions during the development of bleomycin-induced lung injury in rats. <i>Exp Toxicol Pathol</i>. 2003;55(1):21-32. [PMID: 12940625]</p>\n<p>7. Adach K, Suzuki M, Sugimoto T, et al. Granulocyte colony-stimulating factor exacerbates the acute lung injury and pulmonary fibrosis induced by intratracheal administration of bleomycin in rats. <i>Exp Toxicol Pathol</i>. 2002;53(6):501-510. [PMID: 11926293]</p>\n<p>8. Andreutti D, Gabbiani G, Neuville P. Early granulocyte-macrophage colony-stimulating factor expression by alveolar inflammatory cells during bleomycin-induced rat lung fibrosis. <i>Lab Invest</i>. 1998;78(12):1493-1502. [PMID: 9881949]</p>\n<p>9. Saxman SB, Nichols CR, Einhorn LH. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. <i>Chest</i>. 1997;111(3):657-660. [PMID: 9118704]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10408":"<p><b>Title</b> Cyclophosphamide / Lenograstim</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lenograstim may enhance the adverse/toxic effect of Cyclophosphamide. Specifically, the risk of pulmonary toxicity may be enhanced. Cyclophosphamide may diminish the therapeutic effect of Lenograstim. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of lenograstim 24 hours before until 24 hours after the completion of bleomycin infusion. Consider monitoring for enhanced pulmonary toxicity when cyclophosphamide and lenograstim are given in combination.</p> \n<p><b>Discussion</b> Lenograstim product labeling states that the safety and efficacy of lenograstim administered on the same day as myelosuppressive cytotoxic chemotherapy, such as cyclophosphamide, has not been established.<sup>1,2</sup> Since rapidly dividing myeloid cells (ie, those stimulated by use of lenograstim) are particularly sensitive to the effects of myelosuppressive cytotoxic chemotherapy, the use of lenograstim should not precede or overlap the administration of cytotoxic chemotherapy.<sup>1,2</sup> It is recommended that lenograstim should start at least 24 hours after the completion of chemotherapy.<sup>1,2</sup><br><br>In addition to reduced lenograstim efficacy, the combined use of cyclophosphamide and lenograstim may increase the risk for pulmonary toxicity. Cyclophosphamide US prescribing information warns that its use in combination with a granulocyte colony-stimulating factor (ie, lenograstim) may increase the risk of pulmonary toxicity.<sup>3,4</sup> Several published reports describe pulmonary toxicity, sometimes severe or fatal, occurring in patients given colony-stimulating factors during treatment with chemotherapeutic regimens including cyclophosphamide.<sup>5,6,7</sup> The mechanism of this possible interaction is not clear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Granocyte (lenograstim) [summary of product characteristics]. Turnham Green, London, UK: Chugai Pharma UK Limited; April 2015.</p>\n<p>2. Granocyte (lenograstim) [summary of product characteristics]. Melbourne, Australia: Hospira Australia Pty Ltd; April 2016.</p>\n<p>3. Cyclophosphamide [prescribing information]. Columbus, OH: Roxane Laboratories Inc; September 2013.</p>\n<p>4. Cyclophosphamide [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; May 2013.</p>\n<p>5. Couderc LJ, Stelianides S, Frachon I, et al. Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases. <i>Respir Med</i>. 1999;93(1):65-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10464852\">[PubMed 10464852]</a></p>\n<p>6. Yokose N, Ogata K, Tamura H, et al. Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma. <i>Br J Cancer</i>. 1998;77(12):2286-2290. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9649147\">[PubMed 9649147]</a></p>\n<p>7. Lei KI, Leung WT, Johnson PJ. Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma. <i>Br J Cancer</i>. 1994;70(5):1009-1013. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7524599\">[PubMed 7524599]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10409":"<p><b>Title</b> Opioid Analgesics / Nalmefene</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nalmefene may diminish the therapeutic effect of Opioid Analgesics. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of nalmefene and opioid analgesics. Discontinue nalmefene 1 week prior to any anticipated use of opioid analgesics (eg, elective surgery). If combined, larger doses of opioid analgesics will likely be required.</p>\n<div>\n <p><b>Opioid Analgesics Interacting Members</b> Alfentanil, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, FentaNYL, Heroin, HYDROcodone, HYDROmorphone, Levorphanol, Meperidine, Meptazinol, Methadone, Morphine (Liposomal), Morphine (Systemic), Nalbuphine, Opium, Opium Tincture, OxyCODONE, OxyMORphone, Paregoric, Pentazocine, Remifentanil, SUFentanil, Tapentadol, TraMADol</p>\n</div> \n<p><b>Discussion</b> The nalmefene product label states that concomitant use of nalmefene in patients taking chronic opioid therapy is contraindicated due to the risk of precipitating opioid withdrawal symptoms.<sup>1</sup> Nalmefene should be discontinued 1 week prior to any anticipated use of opioid analgesics.<sup>1</sup> In an emergency situation where opioids must be administered to a patient taking nalmefene, the amount of opioid required to obtain the desired effect may be greater than usual.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Selincro (nalmefene) [summary of product characteristics]. Milton Keynes, UK: Lundbeck Limited; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10410":"<p><b>Title</b> Nalmefene / Meclofenamate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Meclofenamate may increase the serum concentration of Nalmefene. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor or increased nalmefene effects/toxicities if combined with meclofenamate.</p> \n<p><b>Discussion</b> The nalmefene product label states that since in vitro studies have shown that nalmefene is primarily metabolized by glucuronosyltransferase 2B7 (UGT2B7), concomitant use of medications that inhibit UGT2B7 may lead to increased nalmefene exposure and effects.<sup>1</sup> Product labeling specifically lists diclofenac, fluconazole, medroxyprogesterone acetate, and meclofenamate as examples of UGT2B7 inhibitors.<sup>1</sup> No clinical studies have been conducted to evaluate the effect of UGT2B7 inhibition on nalmefene pharmacokinetics.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Selincro (nalmefene) [summary of product characteristics]. Milton Keynes, UK: Lundbeck Limited; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10411":"<p><b>Title</b> Nalmefene / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Nalmefene. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor or increased nalmefene effects/toxicities if combined with fluconazole.</p> \n<p><b>Discussion</b> The nalmefene product label states that since in vitro studies have shown that nalmefene is primarily metabolized by glucuronosyltransferase 2B7 (UGT2B7), concomitant use of medications that inhibit UGT2B7 may lead to increased nalmefene exposure and effects.<sup>1</sup> Product labeling specifically lists diclofenac, fluconazole, medroxyprogesterone acetate, and meclofenamate as examples of UGT2B7 inhibitors.<sup>1</sup> No clinical studies have been conducted to evaluate the effect of UGT2B7 inhibition on nalmefene pharmacokinetics.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Selincro (nalmefene) [summary of product characteristics]. Milton Keynes, UK: Lundbeck Limited; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10412":"<p><b>Title</b> Nalmefene / Diclofenac (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Diclofenac (Systemic) may increase the serum concentration of Nalmefene. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor or increased nalmefene effects/toxicities if combined with diclofenac.</p> \n<p><b>Discussion</b> The nalmefene product label states that since in vitro studies have shown that nalmefene is primarily metabolized by glucuronosyltransferase 2B7 (UGT2B7), concomitant use of medications that inhibit UGT2B7 may lead to increased nalmefene exposure and effects.<sup>1</sup> Product labeling specifically lists diclofenac, fluconazole, medroxyprogesterone acetate, and meclofenamate as examples of UGT2B7 inhibitors.<sup>1</sup> No clinical studies have been conducted to evaluate the effect of UGT2B7 inhibition on nalmefene pharmacokinetics.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Selincro (nalmefene) [summary of product characteristics]. Milton Keynes, UK: Lundbeck Limited; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10413":"<p><b>Title</b> Nalmefene / MedroxyPROGESTERone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MedroxyPROGESTERone may increase the serum concentration of Nalmefene. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor or increased nalmefene effects/toxicities if combined with medroxyprogesterone.</p> \n<p><b>Discussion</b> The nalmefene product label states that since in vitro studies have shown that nalmefene is primarily metabolized by glucuronosyltransferase 2B7 (UGT2B7), concomitant use of medications that inhibit UGT2B7 may lead to increased nalmefene exposure and effects.<sup>1</sup> Product labeling specifically lists diclofenac, fluconazole, medroxyprogesterone acetate, and meclofenamate as examples of UGT2B7 inhibitors.<sup>1</sup> No clinical studies have been conducted to evaluate the effect of UGT2B7 inhibition on nalmefene pharmacokinetics.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Selincro (nalmefene) [summary of product characteristics]. Milton Keynes, UK: Lundbeck Limited; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10414":"<p><b>Title</b> Nalmefene / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease the serum concentration of Nalmefene. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased nalmefene effects/therapeutic failure if combined with dexamethasone.</p> \n<p><b>Discussion</b> The nalmefene product label states that since in vitro studies have shown that nalmefene is primarily metabolized by glucuronosyltransferase 2B7 (UGT2B7), concomitant use of medications that induce UGT2B7 may lead to decreased nalmefene exposure and effects.<sup>1</sup> Product labeling specifically lists dexamethasone, rifampin, phenobarbital and omeprazole as examples of UGT2B7 inducers.<sup>1</sup> No clinical studies have been conducted to evaluate the effect of UGT2B7 induction on nalmefene pharmacokinetics.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Selincro (nalmefene) [summary of product characteristics]. Milton Keynes, UK: Lundbeck Limited; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10415":"<p><b>Title</b> Nalmefene / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Nalmefene. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased nalmefene effects/therapeutic failure if combined with rifampin.</p> \n<p><b>Discussion</b> The nalmefene product label states that since in vitro studies have shown that nalmefene is primarily metabolized by glucuronosyltransferase 2B7 (UGT2B7), concomitant use of medications that induce UGT2B7 may lead to decreased nalmefene exposure and effects.<sup>1</sup> Product labeling specifically lists dexamethasone, rifampin, phenobarbital and omeprazole as examples of UGT2B7 inducers.<sup>1</sup> No clinical studies have been conducted to evaluate the effect of UGT2B7 induction on nalmefene pharmacokinetics.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Selincro (nalmefene) [summary of product characteristics]. Milton Keynes, UK: Lundbeck Limited; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10416":"<p><b>Title</b> Nalmefene / PHENobarbital</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> PHENobarbital may decrease the serum concentration of Nalmefene. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased nalmefene effects/therapeutic failure if combined with phenobarbital.</p> \n<p><b>Discussion</b> The nalmefene product label states that since in vitro studies have shown that nalmefene is primarily metabolized by glucuronosyltransferase 2B7 (UGT2B7), concomitant use of medications that induce UGT2B7 may lead to decreased nalmefene exposure and effects.<sup>1</sup> Product labeling specifically lists dexamethasone, rifampin, phenobarbital and omeprazole as examples of UGT2B7 inducers.<sup>1</sup> No clinical studies have been conducted to evaluate the effect of UGT2B7 induction on nalmefene pharmacokinetics.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Selincro (nalmefene) [summary of product characteristics]. Milton Keynes, UK: Lundbeck Limited; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10417":"<p><b>Title</b> Nalmefene / Omeprazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Omeprazole may decrease the serum concentration of Nalmefene. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased nalmefene effects/therapeutic failure if combined with omeprazole.</p> \n<p><b>Discussion</b> The nalmefene product label states that since in vitro studies have shown that nalmefene is primarily metabolized by glucuronosyltransferase 2B7 (UGT2B7), concomitant use of medications that induce UGT2B7 may lead to decreased nalmefene exposure and effects.<sup>1</sup> Product labeling specifically lists dexamethasone, rifampin, phenobarbital and omeprazole as examples of UGT2B7 inducers.<sup>1</sup> No clinical studies have been conducted to evaluate the effect of UGT2B7 induction on nalmefene pharmacokinetics.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Selincro (nalmefene) [summary of product characteristics]. Milton Keynes, UK: Lundbeck Limited; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10418":"<p><b>Title</b> Nalmefene / Primidone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Primidone may decrease the serum concentration of Nalmefene. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased nalmefene effects/therapeutic failure if combined with primidone.</p> \n<p><b>Discussion</b> The nalmefene product label states that since in vitro studies have shown that nalmefene is primarily metabolized by glucuronosyltransferase 2B7 (UGT2B7), concomitant use of medications that induce UGT2B7 may lead to decreased nalmefene exposure and effects.<sup>1</sup> Product labeling specifically lists dexamethasone, rifampin, omeprazole and phenobarbital (the active metabolite of primidone) as examples of UGT2B7 inducers.<sup>1</sup> No clinical studies have been conducted to evaluate the effect of UGT2B7 induction on nalmefene pharmacokinetics.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Selincro (nalmefene) [summary of product characteristics]. Milton Keynes, UK: Lundbeck Limited; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10419":"<p><b>Title</b> Losartan / Resveratrol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Resveratrol may decrease serum concentrations of the active metabolite(s) of Losartan. Resveratrol may increase the serum concentration of Losartan. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for changes in losartan effects if combined with resveratrol. The antihypertensive action of losartan may be enhanced or diminished when combined with resveratrol.</p> \n<p><b>Discussion</b> In a study of 41 healthy volunteers, coadministration of resveratrol (1,000 mg daily x 4 weeks) and losartan (25 mg single dose) increased the losartan to E3174 (the active metabolite of losartan) ratio by 171%.<sup>1</sup><br><br>The likely mechanism for this interaction is resveratrol inhibition of CYP2C9, the major metabolic enzyme responsible for conversion of losartan to E3174.<sup>2</sup> E3174 is thought to be significantly more potent than losartan and may be responsible for the majority of the angiotensin II receptor antagonism and therapeutic effect.<sup>2,3</sup> Because the clinical consequences of this interaction (altered ratio of losartan to E3174) are unknown, losartan effects should be closely monitored when combined with resveratrol.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Chow HH, Garland LL, Hsu CH, et al. Resveratrol modulates drug- and carcinogren-metabolizing enzymes in a healthy volunteer study. <i>Cancer Prev Res (Phila)</i>. 2010;3(9):1168-11175. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20716633\">[PubMed 20716633]</a></p>\n<p>2. Cozaar (losartan) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; December 2015.</p>\n<p>3. Munafo A, Christen Y, Nussberger J, et al. Drug concentration relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. <i>Clin Pharmacol Ther</i>. 1992;51(5):513-521. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1587065\">[PubMed 1587065]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10420":"<p><b>Title</b> Codeine / Monoamine Oxidase Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: This combination is contraindicated in Canadian labeling but not specifically included in US labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Codeine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of acetaminophen and codeine with a monoamine oxidase inhibitor (MAOI), or within 14 days of an MAOI, is contraindicated according to the Canadian labeling for acetaminophen and codeine products. The U.S. labeling for such products does not contraindicate the combination, but caution should be exercised with any combined use due to the possibility of serotonin toxicity or other adverse events.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The Canadian labeling for both the acetaminophen, caffeine and codeine and acetaminophen and codeine combination products lists use with a monoamine oxidase inhibitor (MAOI), or within 14 days of an MAOI, as contraindicated.<sup>1</sup> Although this warning is not in the U.S. labeling for these products, the US Food and Drug Administration issued a warning about the potential for opioids, such as codeine, to cause serotonergic toxicity when used with serotonin-modulating drugs, such as MAOIs. Whether this concern is the source for the Canadian label contraindication is uncertain as no additional detail is provided regarding the potential interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tylenol with Codeine (acetaminophen, caffeine and codeine; acetaminophen and codeine) [prescribing information]. Markham, Ontario, Canada: Janssen Inc.; February 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10421":"<p><b>Title</b> Etoposide Phosphate / Atovaquone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Atovaquone may increase the serum concentration of Etoposide Phosphate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased etoposide effects/toxicities if combined with atovaquone. To minimize this potential interaction, consider separating the administration of atovaquone and etoposide by 1 to 2 days.</p> \n<p><b>Discussion</b> In a small crossover study, pediatric patients undergoing continuation chemotherapy (approximately 1 year) for acute lymphoblastic leukemia (ALL) received pneumocystis prophylactic therapy with either atovaquone (45 mg/kg BID x7days) or trimethoprim/sulfamethoxazole (TMP/SMX) (150 mg/750 mg/m<sup>2</sup> BID x7days) at weeks 45 and 53, prior to etoposide (300 mg/m<sup>2</sup> x1 dose) at weeks 46 and 54. When compared to TMP/SMX, atovaquone therapy increased the AUC of both etoposide (9%) and its catechol metabolite (28%) and also increased catechol/etoposide ratio (26%).<sup>1</sup> <br><br>The precise mechanism behind the observed interaction is not known. The authors of this study speculated and evaluated (in vitro) the influence of atovaquone on etoposide metabolism/transport via cytochrome P450 and P-glycoprotein (P-gp). Atovaquone was found to inhibit etoposide catechol formation while weakly inhibiting P-gp-mediated transport. Though cytochrome P450 inhibition might possibly explain the increased etoposide levels observed in the study subjects, it does not completely explain the increased catechol levels observed.<br><br>Increased etoposide exposure may lead to toxicity including development of secondary malignancy. To reduce the likelihood of an interaction and increased etoposide exposure, the authors of this study have suggested separating atovaquone and etoposide administration by at least 1 to 2 days. Of note, studies of pediatric patients with secondary malignancy (acute myeloid leukemia) suggest that frequency of etoposide administration (weekly, twice weekly) more so than cumulative dose, may be associated with a greater risk for secondary disease development.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. van de Poll ME, Relling MV, Schuetz EG, Harrison PL, Hughes W, Flynn PM. The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia. <i>Cancer Chemother Pharmacol</i>. 2001;47(6):467-472. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11459198\">[PubMed 11459198]</a></p>\n<p>2. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. <i>N Engl J Med</i>. 1991;325(24):1682-1687. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1944468\">[PubMed 1944468]</a></p>\n<p>3. Sugita K, Furukawa T, Tsuchida M, et al. High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma. <i>Am J Pediatr Hematol Oncol</i>. 1993;15(1):99-104. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8447565\">[PubMed 8447565]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10422":"<p><b>Title</b> Daclatasvir / OXcarbazepine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian daclatasvir prescribing information states that the combination of daclatasvir and oxcarbazepine is contraindicated. The combination is not included as a potential interaction in US daclatasvir prescribing information.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> OXcarbazepine may decrease the serum concentration of Daclatasvir. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the daclatasvir prescribing information, the strong CYP3A4 inducer rifampin (600 mg daily) decreased the daclatasvir (60 mg single dose) AUC and maximum serum concentration 79% and 56%, respectively.<sup>1</sup><br><br>US and Canadian daclatasvir product labeling states that concomitant use of daclatasvir and a strong CYP3A4 inducer is contraindicated due to the risk of decreased daclatasvir concentrations, loss of virologic response, and possible development of resistance.<sup>1,2</sup> The Canadian product monograph classifies oxcarbazepine as a strong CYP3A4 inducer,<sup>2</sup> while the US daclatasvir prescribing information does not.<sup>1</sup> Available data suggests that oxcarbazepine is only a weak CYP3A4 inducer.<sup>3</sup><br><br>The mechanism of this interaction is likely increased CYP3A4-mediated metabolism of daclatasvir due to induction of CYP3A4 by strong CYP3A4 inducers.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Daklinza (daclatasvir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; February 2016.</p>\n<p>2. Daklinza (daclatasvir) [product monograph]. Montreal, Quebec, Canada: Bristol-Myers Squibb Canada; August 2015.</p>\n<p>3. Trileptal (oxcarbazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Co; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10424":"<p><b>Title</b> Azithromycin (Systemic) / Aluminum Hydroxide</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction is only expected following oral administration of both agents.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Aluminum Hydroxide may decrease the serum concentration of Azithromycin (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 10 healthy volunteers, administration just after aluminum hydroxide/magnesium hydroxide (1,350/1,200 mg single oral dose) decreased azithromycin (500 mg single oral dose) maximum serum concentration (Cmax) by 24% without affecting time to maximum concentration or AUC.<sup>1</sup> The clinical significance of these data is questionable given the magnitude of effect and the expected correlation between azithromycin efficacy and its AUC rather than Cmax.<sup>2</sup> Information on this potential interaction was included in azithromycin US prescribing information for professionals as recently as 2013, but has since been removed.<sup>3,4</sup> A recommendation still included in azithromycin Patient Counseling Information states that patients should be cautioned not to take azithromycin and aluminum- or magnesium-containing antacids simultaneously.<sup>4</sup><br><br>The mechanism of this interaction is unclear. Administration of cimetidine 2 hours before azithromycin had no impact on azithromycin pharmacokinetic variables in a clinical study, which suggesting a lack of impact of increased pH on azithromycin absorption.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Foulds G, Hilligoss DM, Henry EB, Gerber N. The effects of an antacid or cimetidine on the serum concentrations of azithromycin. <i>J Clin Pharmacol</i>. 1991;31(2):164-167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1849152\">[PubMed 1849152]</a></p>\n<p>2. Maglio D, Nicolau DP, Nightingale CH. Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides. <i>Infect Dis Clin North Am</i>. 2003;17(3):563-577. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14711077\">[PubMed 14711077]</a></p>\n<p>3. Zithromax (azithromycin) [prescribing information]. New York, NY: Pfizer Inc; February 2013.</p>\n<p>4. Zithromax (azithromycin) [prescribing information]. New York, NY: Pfizer Inc; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10425":"<p><b>Title</b> Azithromycin (Systemic) / Magnesium Hydroxide</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction is only expected following oral administration of both agents.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Magnesium Hydroxide may decrease the serum concentration of Azithromycin (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 10 healthy volunteers, administration just after aluminum hydroxide/magnesium hydroxide (1,350/1,200 mg single oral dose) decreased azithromycin (500 mg single oral dose) maximum serum concentration (Cmax) by 24% without affecting time to maximum concentration or AUC.<sup>1</sup> The clinical significance of these data is questionable given the magnitude of effect and the expected correlation between azithromycin efficacy and its AUC rather than Cmax.<sup>2</sup> Information concerning this potential interaction was included in azithromycin US prescribing information for professionals as recently as 2013, but has since been removed.<sup>3,4</sup> A recommendation is still included in azithromycin Patient Counseling Information stating that patients should cautioned not to take azithromycin and aluminum- or magnesium-containing antacids simultaneously.<sup>4</sup><br><br>The mechanism of this interaction is unclear. Administration of cimetidine 2 hr before azithromycin had no impact on azithromycin pharmacokinetic variables in a clinical study, which suggests a lack of impact of increased pH on azithromycin absorption.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Foulds G, Hilligoss DM, Henry EB, Gerber N. The effects of an antacid or cimetidine on the serum concentrations of azithromycin. <i>J Clin Pharmacol</i>. 1991;31(2):164-167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1849152\">[PubMed 1849152]</a></p>\n<p>2. Maglio D, Nicolau DP, Nightingale CH. Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides. <i>Infect Dis Clin North Am</i>. 2003;17(3):563-577. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14711077\">[PubMed 14711077]</a></p>\n<p>3. Zithromax (azithromycin) [prescribing information]. New York, NY: Pfizer Inc; February 2013.</p>\n<p>4. Zithromax (azithromycin) [prescribing information]. New York, NY: Pfizer Inc; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10426":"<p><b>Title</b> Perhexiline / CYP2D6 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2D6 Inhibitors may increase the serum concentration of Perhexiline. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternatives to the combination of CYP2D6 inhibitors and perhexiline. If combined, monitor for increased perhexiline serum concentrations and toxicities (eg, hypoglycemia, neuropathy, liver dysfunction). Perhexiline dose reductions will likely be required.</p>\n<div>\n <p><b>CYP2D6 Inhibitors Interacting Members</b> Abiraterone Acetate, Asunaprevir, BuPROPion, Cinacalcet, Darifenacin, Darunavir, DULoxetine, FLUoxetine, Lorcaserin, Mirabegron, PARoxetine, Perhexiline, QuiNIDine, Rolapitant, Terbinafine (Systemic), Thioridazine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> One case report describes a 63-year-old man who took perhexiline 200 mg daily (serum concentrations less than 0.6 mg/L) for several years and experienced nausea and increased perhexiline serum concentrations (1.39 mg/L) after initiation of the strong CYP2D6 inhibitor terbinafine.<sup>1</sup> Another report describes patients who experienced significantly elevated perhexiline concentrations (greater than 1.5 mg/L) after the addition of the strong CYP2D6 inhibitors paroxetine or fluoxetine.<sup>2</sup><br><br>Perhexiline product labeling states that concomitant use with CYP2D6 inhibitors will likely result in significant increases in perhexiline concentrations.<sup>3</sup> Perhexiline serum concentrations should be closely monitored with dose adjustments made as needed to ensure that concentrations remain below 0.6 mg/L.<sup>3</sup> <br><br>Perhexiline is extensively metabolized by CYP2D6,<sup>3,4,5,6</sup> and extensive CYP2D6 metabolizers have a perhexiline oral clearance that is 10-fold to 16-fold higher than perhexiline oral clearance in poor CYP2D6 metabolizers.<sup>4</sup> The mechanism of this interaction is inhibition of CYP2D6-mediated perhexiline metabolism by CYP2D6 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sheikh AR, Westley I, Sallustio B, Horowitz JD, Beltrame JF. Interaction of terbinafine (anti-fungal agent) with perhexiline: a case report. <i>Heart Lung Circ</i>. 2014;23(6):e149-e151. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24373912\">[PubMed 24373912]</a></p>\n<p>2. Alderman CP, Hundertmark JD, Soetratma TW. Interaction of serotonin re-uptake inhibitors with perhexiline. <i>Aust N Z J Psychiatry</i>. 1997;31(4):601-603. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9272272\">[PubMed 9272272]</a></p>\n<p>3. Pexsig (perhexiline) [summary of product characteristics]. St Leonards, New South Wales, Australia: Aspen Pharma Pty Ltd; March 2009.</p>\n<p>4. Davies BJ, Herbert MK, Coller JK, Somogyi AA, Milne RW, Sallustio BC. Steady-state pharmacokinetics of the enatiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. <i>Br J Clin Pharmacol</i>. 2008;65(3):347-354. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17875193\">[PubMed 17875193]</a></p>\n<p>5. Davies BJ, Coller JK, James HM, Somogyi AA, Horowitz JD, Sallustio BC. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia. <i>Br J Clin Pharmacol</i>. 2006;61(3):321-325. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16487226\">[PubMed 16487226]</a></p>\n<p>6. Inglis SC, Herbert MK, Davies BJ, et al. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia. <i>Pharmacogenet Genomics</i>. 2007;17(5):305-312. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17429312\">[PubMed 17429312]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10427":"<p><b>Title</b> Perhexiline / CYP2D6 Inhibitors (Weak)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Weak) may increase the serum concentration of Perhexiline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased perhexiline concentrations and toxicities (eg, hypoglycemia, neuropathy, liver dysfunction) if combined with a weak CYP2D6 inhibitor.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Weak) Interacting Members</b> Amiodarone, Asenapine, Celecoxib, Cimetidine, Citalopram, CloBAZam, Cobicistat, Desvenlafaxine, DilTIAZem, DiphenhydrAMINE (Systemic), Dronedarone, Eliglustat, Escitalopram, Felodipine, Gefitinib, Goldenseal, Methadone, Moclobemide, NiCARdipine, Panobinostat, Propafenone, Ranolazine, Sarpogrelate, Sertraline, Telithromycin, Ticlopidine, Vemurafenib, Venlafaxine</p>\n</div> \n<p><b>Discussion</b> One case report describes a 63-year-old man who took perhexiline 200 mg daily (serum concentrations less than 0.6 mg/L) for several years and experienced nausea and increased perhexiline serum concentrations (1.39 mg/L) after initiation of the strong CYP2D6 inhibitor terbinafine.<sup>1</sup> Another report describes patients who experienced significantly elevated perhexiline concentrations (greater than 1.5 mg/L) after the addition of the strong CYP2D6 inhibitors paroxetine or fluoxetine.<sup>2</sup> Lastly, an 82-year-old man experienced nausea, diarrhea, and dizziness along with an elevated perhexiline serum concentration (0.82 mg/L) 10 days after the weak CYP2D6 inhibitor citalopram was added to his perhexiline therapy.<sup>3</sup><br><br>Perhexiline product labeling states that concomitant use with CYP2D6 inhibitors will likely result in significant increases in perhexiline concentrations.<sup>4</sup> Perhexiline serum concentrations should be closely monitored with dose adjustments made as needed to ensure that concentrations remain below 0.6 mg/L.<sup>4</sup> <br><br>Perhexiline is extensively metabolized by CYP2D6,<sup>4,5,6,7</sup> and extensive CYP2D6 metabolizers have a perhexiline oral clearance that is 10-fold to 16-fold higher than perhexiline oral clearance in poor CYP2D6 metabolizers.<sup>5</sup> The mechanism of this interaction is inhibition of CYP2D6-mediated perhexiline metabolism by CYP2D6 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sheikh AR, Westley I, Sallustio B, Horowitz JD, Beltrame JF. Interaction of terbinafine (anti-fungal agent) with perhexiline: a case report. <i>Heart Lung Circ</i>. 2014;23(6):e149-e151. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24373912\">[PubMed 24373912]</a></p>\n<p>2. Alderman CP, Hundertmark JD, Soetratma TW. Interaction of serotonin re-uptake inhibitors with perhexiline. <i>Aust N Z J Psychiatry</i>. 1997;31(4):601-603. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9272272\">[PubMed 9272272]</a></p>\n<p>3. Nyfort-Hansen K. Perhexiline toxicity related to citalopram use. <i>Med J Aust</i>. 2002;176(11):560-561. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12064991\">[PubMed 12064991]</a></p>\n<p>4. Pexsig (perhexiline) [summary of product characteristics]. St Leonards, New South Wales, Australia: Aspen Pharma Pty Ltd; March 2009.</p>\n<p>5. Davies BJ, Herbert MK, Coller JK, Somogyi AA, Milne RW, Sallustio BC. Steady-state pharmacokinetics of the enatiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. <i>Br J Clin Pharmacol</i>. 2008;65(3):347-354. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17875193\">[PubMed 17875193]</a></p>\n<p>6. Davies BJ, Coller JK, James HM, Somogyi AA, Horowitz JD, Sallustio BC. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia. <i>Br J Clin Pharmacol</i>. 2006;61(3):321-325. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16487226\">[PubMed 16487226]</a></p>\n<p>7. Inglis SC, Herbert MK, Davies BJ, et al. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia. <i>Pharmacogenet Genomics</i>. 2007;17(5):305-312. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17429312\">[PubMed 17429312]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10428":"<p><b>Title</b> CYP2D6 Substrates (High risk with Inhibitors) / Perhexiline</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased perhexiline concentrations and toxicities (eg, hypoglycemia, neuropathy, liver dysfunction) if combined with a CYP2D6 substrate. Additionally, monitor for increased CYP2D6 substrate concentrations and effects (or decreased effects if the substrate is a prodrug that is converted to an active moiety by CYP2D6) if combined with perhexiline.</p>\n<div>\n <p><b>CYP2D6 Substrates (High risk with Inhibitors) Interacting Members</b> Ajmaline, Amitriptyline, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, AtoMOXetine, Brexpiprazole, Captopril, Carvedilol, Chloroquine, Chlorpheniramine, ChlorproMAZINE, ClomiPRAMINE, Codeine, Dapoxetine, Desipramine, Deutetrabenazine, Dextromethorphan, Doxepin (Systemic), Doxepin (Topical), DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eliglustat, Flecainide, FLUoxetine, FluPHENAZine, FluvoxaMINE, Gefitinib, Haloperidol, Iloperidone, Imipramine, Indoramin, Maprotiline, Mequitazine, Methamphetamine, Metoprolol, Mexiletine, Mirtazapine, Nefazodone, Nortriptyline, Olmutinib, PARoxetine, Perhexiline, Perphenazine, Pimozide, Primaquine, Procainamide, Propafenone, Propranolol, Protriptyline, RisperiDONE, Syrian Rue, Tamoxifen, Tetrabenazine, Thioridazine, Timolol (Ophthalmic), Timolol (Systemic), Tolterodine, Trimipramine, Tropisetron, Venlafaxine, Vortioxetine, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Perhexiline is extensively metabolized by CYP2D6,<sup>1,2,3,4</sup> and extensive CYP2D6 metabolizers have a perhexiline oral clearance that is 10-fold to 16-fold higher than perhexiline oral clearance in poor CYP2D6 metabolizers.<sup>2</sup> The CYP2D6 metabolism of perhexiline is saturable and does not exhibit linear pharmacokinetics.<sup>1</sup> Although no clinical data are available, because of the high reliance on CYP2D6 for clearance and the saturable nature of CYP2D6 metabolism, the perhexiline prescribing information states that concomitant use with CYP2D6 substrates may lead to increased perhexiline concentrations.<sup>1</sup> Perhexiline serum concentrations should be monitored, with dose adjustments made as needed, to ensure that concentrations remain below 0.6 mg/L.<sup>1</sup><br><br>In addition to the potential for CYP2D6 substrates to increase perhexiline concentrations, perhexiline may lead to increased concentrations of CYP2D6 substrates. In a clinical study, the urinary dextrorphan to dextromethorphan metabolic ratio (a measure of CYP2D6 activity) was significantly higher in 8 placebo-treated patients compared with 24 perhexiline-treated patients (ratios of 271 vs 5, respectively).<sup>5</sup> In the perhexiline-treated group, 10 patients (42%) had a metabolic ratio consistent with a poor metabolizer phenotype. However, no patients had genotypes consistent with a poor CYP2D6 metabolizer status, suggesting that the presence of perhexiline converted patients to poor metabolizers by inhibiting CYP2D6.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pexsig (perhexiline) [summary of product characteristics]. St Leonards, New South Wales, Australia: Aspen Pharma Pty Ltd; March 2009.</p>\n<p>2. Davies BJ, Herbert MK, Coller JK, Somogyi AA, Milne RW, Sallustio BC. Steady-state pharmacokinetics of the enatiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered rac-perhexiline. <i>Br J Clin Pharmacol</i>. 2008;65(3):347-354. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17875193\">[PubMed 17875193]</a></p>\n<p>3. Davies BJ, Coller JK, James HM, Somogyi AA, Horowitz JD, Sallustio BC. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia. <i>Br J Clin Pharmacol</i>. 2006;61(3):321-325. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16487226\">[PubMed 16487226]</a></p>\n<p>4. Inglis SC, Herbert MK, Davies BJ, et al. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia. <i>Pharmacogenet Genomics</i>. 2007;17(5):305-312. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17429312\">[PubMed 17429312]</a></p>\n<p>5. Davies BJ, Coller JK, James HM, et al. Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline. <i>Br J Clin Pharmacol</i>. 2004;57(4):456-463. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15025744\">[PubMed 15025744]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10429":"<p><b>Title</b> DOXOrubicin (Conventional) / Perhexiline</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Perhexiline may enhance the adverse/toxic effect of DOXOrubicin (Conventional). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is required beyond the routine monitoring that accompanies doxorubicin use.</p> \n<p><b>Discussion</b> In vitro studies suggest that perhexiline may enhance the sensitivity of cells to the cytotoxic effects of doxorubicin.<sup>1,2,3</sup> Perhexiline prescribing information states that the concomitant use of perhexiline and doxorubicin may cause an increase in cellular doxorubicin concentrations and lead to increased doxorubicin toxicities.<sup>4</sup> <br><br>In contrast, the increased doxorubicin sensitivity associated with perhexiline use has only been seen in cells with acquired doxorubicin resistance (ie, cancer cells).<sup>1,2,3</sup> This suggests that concomitant use of perhexiline may lead to increased doxorubicin efficacy, but may not affect healthy cells or lead to increased toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cole SP, Downes HF, Slovak ML. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein. <i>Br J Cancer</i>. 1989;59(1):42-46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2569325\">[PubMed 2569325]</a></p>\n<p>2. Foster BJ, Grotzinger KR, McKoy WM, Rubinstein LV, Hamilton TC. Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate. <i>Cancer Chemother Pharmacol</i>. 1988;22(2):147-152. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3409446\">[PubMed 3409446]</a></p>\n<p>3. Ramu A, Fuks Z, Gatt S, Glaubiger D. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate. <i>Cancer Res</i>. 1984;44(1):144-148. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6690032\">[PubMed 6690032]</a></p>\n<p>4. Pexsig (perhexiline) [summary of product characteristics]. St Leonards, New South Wales, Australia: Aspen Pharma Pty Ltd; March 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10430":"<p><b>Title</b> DOXOrubicin (Liposomal) / Perhexiline</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Perhexiline may enhance the adverse/toxic effect of DOXOrubicin (Liposomal). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is required beyond the routine monitoring that accompanies doxorubicin use.</p> \n<p><b>Discussion</b> In vitro studies suggest that perhexiline may enhance the sensitivity of cells to the cytotoxic effects of doxorubicin.<sup>1,2,3</sup> Perhexiline prescribing information states that the concomitant use of perhexiline and doxorubicin may cause an increase in cellular doxorubicin concentrations and lead to increased doxorubicin toxicities.<sup>4</sup> <br><br>In contrast, the increased doxorubicin sensitivity associated with perhexiline use has only been seen in cells with acquired doxorubicin resistance (ie, cancer cells).<sup>1,2,3</sup> This suggests that concomitant use of perhexiline may lead to increased doxorubicin efficacy, but may not affect healthy cells or lead to increased toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cole SP, Downes HF, Slovak ML. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein. <i>Br J Cancer</i>. 1989;59(1):42-46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2569325\">[PubMed 2569325]</a></p>\n<p>2. Foster BJ, Grotzinger KR, McKoy WM, Rubinstein LV, Hamilton TC. Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate. <i>Cancer Chemother Pharmacol</i>. 1988;22(2):147-152. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3409446\">[PubMed 3409446]</a></p>\n<p>3. Ramu A, Fuks Z, Gatt S, Glaubiger D. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate. <i>Cancer Res</i>. 1984;44(1):144-148. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6690032\">[PubMed 6690032]</a></p>\n<p>4. Pexsig (perhexiline) [summary of product characteristics]. St Leonards, New South Wales, Australia: Aspen Pharma Pty Ltd; March 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10431":"<p><b>Title</b> Mirodenafil / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mirodenafil. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider using a lower dose of mirodenafil when used with strong CYP3A4 inhibitors. Monitor for increased mirodenafil effects/toxicities with the use of this combination.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 18 healthy volunteers, the strong CYP3A4 inhibitor ketoconazole (400 mg daily x 3 days) increased the mirodenafil (100 mg single dose) AUC and maximum serum concentration 5-fold and 2.8-fold, respectively.<sup>1</sup> More adverse events thought to be due to mirodenafil were reported during coadministration with ketoconazole compared with administration of mirodenafil alone (28 vs 7).<sup>1</sup><br><br>The mechanism of this interaction is likely due to inhibition of CYP3A4-mediated mirodenafil metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shin KH, Kim BH, Kim TE, et al. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. <i>Clin Ther</i>. 2009;31(12):3009-3020. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20110038\">[PubMed 20110038]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10432":"<p><b>Title</b> Mirodenafil / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirodenafil. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider avoiding the concomitant use of mirodenafil and strong CYP3A4 inducers. If combined, monitor for decreased mirodenafil effects. Mirodenafil dose increases may be required to achieve desired effects.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 18 healthy volunteers, the strong CYP3A4 inducer rifampin (600 mg daily x 10 days) decreased the mirodenafil (100 mg single dose) AUC and maximum serum concentration 97% and 95%, respectively.<sup>1</sup><br><br>The mechanism of this interaction is likely due to induction of CYP3A4-mediated mirodenafil metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shin KH, Kim BH, Kim TE, et al. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. <i>Clin Ther</i>. 2009;31(12):3009-3020. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20110038\">[PubMed 20110038]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10433":"<p><b>Title</b> Mirodenafil / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mirodenafil. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased mirodenafil effects/toxicities if combined with moderate CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> No studies have evaluated the concomitant use of mirodenafil and moderate CYP3A4 inhibitors. However, in a pharmacokinetic study of 18 healthy volunteers, the strong CYP3A4 inhibitor ketoconazole (400 mg daily x 3 days) increased the mirodenafil (100 mg single dose) AUC and maximum serum concentration 5-fold and 2.8-fold, respectively.<sup>1</sup> More adverse events thought to be due to mirodenafil were reported during coadministration with ketoconazole compared with administration of mirodenafil alone (28 vs 7).<sup>1</sup><br><br>The mechanism of this interaction is likely due to inhibition of CYP3A4-mediated mirodenafil metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shin KH, Kim BH, Kim TE, et al. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. <i>Clin Ther</i>. 2009;31(12):3009-3020. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20110038\">[PubMed 20110038]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10434":"<p><b>Title</b> Mirodenafil / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mirodenafil. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased mirodenafil effects if combined with moderate CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> No studies have evaluated the concomitant use of mirodenafil and moderate CYP3A4 inducers. However, in a pharmacokinetic study of 18 healthy volunteers, the strong CYP3A4 inducer rifampin (600 mg daily x 10 days) decreased the mirodenafil (100 mg single dose) AUC and maximum serum concentration 97% and 95%, respectively.<sup>1</sup><br><br>The mechanism of this interaction is likely due to induction of CYP3A4-mediated mirodenafil metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shin KH, Kim BH, Kim TE, et al. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. <i>Clin Ther</i>. 2009;31(12):3009-3020. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20110038\">[PubMed 20110038]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10435":"<p><b>Title</b> Mirodenafil / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Mirodenafil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of mirodenafil and grapefruit juice.</p> \n<p><b>Discussion</b> No studies have evaluated the concomitant use of mirodenafil and grapefruit juice. However, in a pharmacokinetic study of 18 healthy volunteers, the strong CYP3A4 inhibitor ketoconazole (400 mg daily x 3 days) increased the mirodenafil (100 mg single dose) AUC and maximum serum concentration 5-fold and 2.8-fold, respectively.<sup>1</sup> More adverse events thought to be due to mirodenafil were reported during coadministration with ketoconazole compared with administration of mirodenafil alone (28 vs 7).<sup>1</sup><br><br>Since grapefruit juice is considered a moderate inhibitor of intestinal CYP3A4, increased exposure to mirodenafil would be expected with coadministration. Product labeling for mirodenafil states that patients should not take grapefruit juice with mirodenafil.<sup>2</sup><br><br>The mechanism of this interaction is likely due to inhibition of CYP3A4-mediated mirodenafil metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shin KH, Kim BH, Kim TE, et al. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. <i>Clin Ther</i>. 2009;31(12):3009-3020. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20110038\">[PubMed 20110038]</a></p>\n<p>2. Mvix 50 mg tablet (mirodenafil) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200708298. Accessed April 7, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10436":"<p><b>Title</b> Sulfonylureas / Mitiglinide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Mitiglinide may enhance the adverse/toxic effect of Sulfonylureas. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of mitiglinide and sulfonylureas.</p>\n<div>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, TOLAZamide, TOLBUTamide</p>\n</div> \n<p><b>Discussion</b> The mitiglinide product label states that due to the similar mechanisms of action of mitiglinide and sulfonylureas and the associated risks of adverse events, these agents should not be combined.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Glufast (mitiglinide calcium hydrate) 5 and 10 mg tablets [prescribing information]. Nagano, Japan: Kissei Pharmaceutical Co Ltd; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10437":"<p><b>Title</b> EPHEDrine (Systemic) / Propofol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Propofol may enhance the therapeutic effect of EPHEDrine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for evidence of exessive blood pressure increase with this combination.</p> \n<p><b>Discussion</b> Several studies have reported an increased pressor response with ephedrine in patients receiving concurrent propofol,<sup>1,2</sup> and clonidine may further increase this risk when used together with propofol.<sup>2,3</sup><br><br>The clinical significance of this effect is uncertain, but the labeling for injectable ephedrine warns about the possible enhanced pressor effect with this combination.<sup>4</sup><br><br>The specific mechanism for this purported interaction is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kanaya N, Satoh H, Seki S, Nakayama M, Namiki A. Propofol anesthesia enhances the pressor response to intravenous ephedrine. <i>Anesth Analg</i>. 2002;94(5):1207-1211. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11973191\">[PubMed 11973191]</a></p>\n<p>2. Hayakawa-Fujii Y, Iida H, Dohi S. Propofol anesthesia enhances pressor response to ephedrine in patients given clonidine. <i>Anesth Analg</i>. 1999;89(1):37-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10389775\">[PubMed 10389775]</a></p>\n<p>3. Ishiyama T, Kashimoto S, Oguchi T, Matsukawa T, Kumazawa T. The effects of clonidine premedication on the blood pressure and tachycardiac responses to ephedrine in elderly and young patients during propofol anesthesia. <i>Anesth Analg</i>. 2003;96(1):136-141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12505939\">[PubMed 12505939]</a></p>\n<p>4. Akovaz (ephedrine) injection. Chesterfield, MO: Eclat Pharmaceuticals; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10438":"<p><b>Title</b> EPHEDrine (Systemic) / CloNIDine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CloNIDine may enhance the therapeutic effect of EPHEDrine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for evidence of exessive blood pressure increase with this combination.</p> \n<p><b>Discussion</b> Several studies have reported an increased pressor response with ephedrine in patients receiving concurrent clonidine,<sup>1,2,3</sup> and propofol may further increase this risk when used together with clonidine.<sup>3,4</sup><br><br>The clinical significance of this effect is uncertain, but the labeling for injectable ephedrine warns about the possible enhanced pressor effect with this combination.<sup>5</sup><br><br>The specific mechanism for this purported interaction is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Goyagi T, Tanaka M, Nishikawa T. Oral clonidine premedication enhances the pressor response to ephedrine during spinal anesthesia. <i>Anesth Analg</i>. 1998;87(6):1336-1339. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9842823\">[PubMed 9842823]</a></p>\n<p>2. Tanaka M, Nishikawa T. Enhancement of pressor response to ephedrine following clonidine medication. <i>Anaesthesia</i>. 1996;51(2):123-127. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8779365\">[PubMed 8779365]</a></p>\n<p>3. Ishiyama T, Kashimoto S, Oguchi T, Matsukawa T, Kumazawa T. The effects of clonidine premedication on the blood pressure and tachycardiac responses to ephedrine in elderly and young patients during propofol anesthesia. <i>Anesth Analg</i>. 2003;96(1):136-141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12505939\">[PubMed 12505939]</a></p>\n<p>4. Hayakawa-Fujii Y, Iida H, Dohi S. Propofol anesthesia enhances pressor response to ephedrine in patients given clonidine. <i>Anesth Analg</i>. 1999;89(1):37-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10389775\">[PubMed 10389775]</a></p>\n<p>5. Akovaz (ephedrine) injection. Chesterfield, MO: Eclat Pharmaceuticals; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10439":"<p><b>Title</b> EPHEDrine (Systemic) / Oxytocin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Oxytocin may enhance the hypertensive effect of EPHEDrine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of excessive blood pressure increase with this combination.</p> \n<p><b>Discussion</b> The labeling for injectable ephedrine states that serious postpartum hypertension has been described in women receiving both oxytocin and ephedrine.<sup>1</sup><br><br>The specific mechanism for this purported interaction is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Akovaz (ephedrine) injection. Chesterfield, MO: Eclat Pharmaceuticals; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10440":"<p><b>Title</b> EPHEDrine (Systemic) / Atropine (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Atropine (Systemic) may enhance the therapeutic effect of EPHEDrine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of exessive blood pressure increase with this combination.</p> \n<p><b>Discussion</b> The labeling for injectable ephedrine states that concurrent use of atropine may result in an enhanced pressor response to ephedrine administration.<sup>1</sup><br><br>The specific mechanism for this purported interaction is not specified, but atropine would be expected to have some additive or synergistic actions resulting from its parasympathetolytic actions, likely enhancing the effects of ephedrine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Akovaz (ephedrine) injection. Chesterfield, MO: Eclat Pharmaceuticals; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10441":"<p><b>Title</b> Rocuronium / EPHEDrine (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> EPHEDrine (Systemic) may enhance the therapeutic effect of Rocuronium. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor closely for a more rapid clinical response to rocuronium in patients who receive ephedrine.</p> \n<p><b>Discussion</b> Pre-treatment with ephedrine was associated with a significantly faster onset of rocuronium effects, shortening the time to onset by an average of 22.3 seconds (22% reduction), according to a meta-analysis of 5 studies involving 282 patients.<sup>1</sup><br><br>The specific mechanism of this reported interaction has been reported to be an increase in cardiac output caused by ephedrine.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dong J, Gao L, Lu W, Xu Z, Zheng J. Pharmacological interventions for acceleration of the onset time of rocuronium: a meta-analysis. <i>PLoS One</i>. 2014;9(12):e114231. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25460931\">[PubMed 25460931]</a></p>\n<p>2. Ezri T, Szmuk P, Warters RD, Gebhard RE, Pivalizza EG, Katz J. Changes in onset time of rocuronium in patients pretreated with ephedrine and esmolol--the role of cardiac output. <i>Acta Anaesthesiol Scand</i>. 2003;47(9):1067-1072. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12969097\">[PubMed 12969097]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10442":"<p><b>Title</b> Cardiac Glycosides / EPHEDrine (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> EPHEDrine (Systemic) may enhance the arrhythmogenic effect of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of new or worsening arrhythmias with this combination.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin</p>\n</div> \n<p><b>Discussion</b> The labeling for injectable ephedrine states that concurrent use of cardiac glycosides may increase the risk for arrhythmias.<sup>1</sup> No other information about this potential interaction is included in the labeling, and no published data describe this interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Akovaz (ephedrine) injection. Chesterfield, MO: Eclat Pharmaceuticals; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10443":"<p><b>Title</b> Flunitrazepam / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of Flunitrazepam. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Advise patients to avoid consuming alcohol during flunitrazepam treatment.</p> \n<p><b>Discussion</b> Flunitrazepam product labeling states that its use in combination with alcohol should be avoided due to the potential for enhanced CNS depressant effects (eg, sedation, respiratory depression).<sup>1,2</sup> Several published reports describe adverse effects resulting from the combined use of these agents, including impaired psychomotor skills and attention, and possibly increases in violent behavior.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hypnodorm [product information]. New South Wales, Australia: Alphapharm Pty Limited; May 2007.</p>\n<p>2. Rohypnol [prescribing information]. Rio de Janeiro RJ, Brasil: Roche Chemicals and Pharmaceuticals SA; May 2014.</p>\n<p>3. Linnoila M, Erwin CW, Brendle A, Logue P. Effects of alcohol and flunitrazepam on mood and performance in healthy young men. <i>J Clin Pharmacol</i>. 1981;21(10):430-435. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6118381\">[PubMed 6118381]</a></p>\n<p>4. Seppala T, Nuotto E, Dreyfus JF. Drug-alcohol interactions on psychomotor skills: zopiclone and flunitrazepam. <i>Pharmacology</i>. 1983;27(suppl 2):127-135. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6669628\">[PubMed 6669628]</a></p>\n<p>5. Daderman AM, Lidberg L. Flunitrazepam (Rohypnol) abuse in combination with alcohol causes premeditated, grievous violence in male juvenile offenders. <i>J Am Acad Psychiatry Law</i>. 1999;27(1):83-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10212029\">[PubMed 10212029]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10444":"<p><b>Title</b> Flunitrazepam / CNS Depressants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use CNS depressants at reduced doses when combined with flunitrazepam, and monitor patients receiving these combinations for evidence of CNS depression (eg, sedation, respiratory depression). Seek non-CNS depressant alternatives when available. Consider the duration of CNS depressant use and each patient's response (particularly tolerance to CNS depressant effects) when selecting and dosing additional agents. Advise patients to avoid alcohol as well as non-prescribed, illicit, or recreational use of other CNS depressants.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Flunitrazepam Brazilian product labeling recommends avoiding use in combination with other CNS depressants due to the potential for enhanced CNS depressant effects (eg, sedation, respiratory depression).<sup>1</sup> Australian labeling states that other CNS depressants should be used at reduced doses (if at all) in patients receiving flunitrazepam, and also states that the potential for sleep-driving and other adverse behavioral effects may be increased with such combinations.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rohypnol [prescribing information]. Rio de Janeiro RJ, Brasil: Roche Chemicals and Pharmaceuticals SA; May 2014.</p>\n<p>2. Hypnodorm [product information]. New South Wales, Australia: Alphapharm Pty Limited; May 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10445":"<p><b>Title</b> Flunitrazepam / Disulfiram</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Disulfiram may increase the serum concentration of Flunitrazepam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients receiving flunitrazepam and disulfiram for evidence of increased effects of flunitrazepam (eg, sedation). Flunitrazepam dose reduction may be needed.</p> \n<p><b>Discussion</b> Flunitrazepam Australian product labeling states that use in combination with disulfiram may increase flunitrazepam plasma levels, in some cases necessitating dose adjustment.<sup>1</sup> Product labeling attributes this possible interaction to the potential for disulfiram to inhibit flunitrazepam metabolism, although no specific enzymes are discussed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hypnodorm [product information]. New South Wales, Australia: Alphapharm Pty Limited; May 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10446":"<p><b>Title</b> Flunitrazepam / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Flunitrazepam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients receiving flunitrazepam and cimetidine for evidence of increased effects of flunitrazepam (eg, sedation). Flunitrazepam dose reduction may be needed.</p> \n<p><b>Discussion</b> Flunitrazepam Australian product labeling states that use in combination with cimetidine may increase flunitrazepam plasma levels, in some cases necessitating dose adjustment.<sup>1</sup> Product labeling attributes this possible interaction to the potential for cimetidine to inhibit flunitrazepam metabolism, although no specific enzymes are discussed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hypnodorm [product information]. New South Wales, Australia: Alphapharm Pty Limited; May 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10447":"<p><b>Title</b> Warfarin / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Grapefruit Juice may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 9 patients receiving stable warfarin treatment (target INR 2 to 3), consumption of 8 ounces of grapefruit juice three times daily for a week had no impact on INR.<sup>1</sup> <br><br>A published case report describes a 64 year old man receiving warfarin (INR target 2-3) whose INR was 6.3 after 10 days of consuming around 1.5 L of grapefruit juice daily.<sup>2</sup> After stopping grapefruit juice and holding warfarin for 2 days, the man resumed his previous warfarin dose. His INR 5 days later was 1.8. Notably, the man's INR was only in the target range 50-60% of the time in the periods before and following grapefruit juice consumption. Additionally, the case report's author himself consumed grapefruit juice (same brand and quantity as reported by the patient) during stable warfarin treatment (2 consecutive INR readings of 2-3) in an attempt to recreate the interaction, without finding any significant change in INR.<br><br>Warfarin isomers are metabolized by several enzymes. Inhibition of intestinal CYP3A function by grapefruit juice could theoretically increase exposure to the less potent R-warfarin isomer. However, grapefruit products are not expected to inhibit hepatic CYP3A-mediated R-warfarin metabolism, nor have any significant impact on exposure to the more potent S-warfarin isomer (primarily metabolized by CYP2C9, the major CYP enzyme involved in clinically relevant warfarin pharmacokinetic interactions).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sullivan DM, Ford MA, Boyden TW. Grapefruit juice and the response to warfarin. <i>Am J Health Syst Pharm</i>. 1998;55(15):1581-1583. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9706183\">[PubMed 9706183]</a></p>\n<p>2. Bartle WR. Grapefruit juice might still be factor in warfarin response. <i>Am J Health Syst Pharm</i>. 1999;56(7):676. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10423213\">[PubMed 10423213]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10448":"<p><b>Title</b> Metaraminol / Inhalational Anesthetics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Inhalational Anesthetics may enhance the arrhythmogenic effect of Metaraminol. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of metaraminol in patients receiving inhalational anesthetics such as halothane. If these agents must be used concurrently, monitor for arrhythmias.</p>\n<div>\n <p><b>Inhalational Anesthetics Interacting Members</b> Desflurane, Halothane, Isoflurane, Sevoflurane</p>\n</div> \n<p><b>Discussion</b> Metaraminol prescribing information states that concomitant use of inhaled anesthetics and metaraminol should be avoided.<sup>1,2</sup> This combination may increase cardiac autonomic irritability and sensitivity to the arrhythmogenic actions of adrenergic stimulation. Although human data evaluating this combination are limited, one report describes numerous patients who developed various arrhythmias with the combination of metaraminol and inhaled anesthetics.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Metaraminol [summary of product characteristics]. Paignton UK: Torbay PMU; June 2015.</p>\n<p>2. Metaraminol [summary of product characteristics]. Sydney NSW, Australia: Montrose Pharma Pty Ltd; January 2014.</p>\n<p>3. Catenacci AJ, Dipalma JR, Anderson JD, King WE. Serious arrhythmias with vasopressors during halothane anesthesia in man. <i>JAMA</i>. 1963;183(8):662-665. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14019327\">[PubMed 14019327]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10449":"<p><b>Title</b> Metaraminol / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Metaraminol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use metaraminol with caution in patients receiving monoamine oxidase inhibitors, and monitor blood pressure response closely.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> No clinical studies have been conducted to evaluate the potential interaction between monoamine oxidase (MAO) inhibitors and metaraminol, but the concomitant use of MAO inhibitors and norepinephrine, another sympathomimetic agent with similar pharmacology, has been evaluated. Published reports of the clinical effects of such combinations are conflicting. A small clinical study of 4 healthy volunteers found no substantial modification of norepinephrine blood pressure effects following 8 days of treatment with phenelzine (45 mg/day).<sup>1</sup> Other human studies have detected no or minimal impact of MAO inhibition on norepinephrine systemic effects.<sup>2,3,4,5</sup> In contrast, in a study of 3 healthy volunteers, heart rate effects of norepinephrine were enhanced in all subjects (1.6- to 4.3-fold) and blood pressure effects were enhanced in 2 of 3 subjects (1.3- to 2.7-fold) following 8 to14 days of tranylcypromine (30 mg/day).<sup>6</sup> In another clinical study of 6 healthy volunteers, blood pressure responses to norepinephrine were greater in 4 of 6 subjects following tranylcypromine pretreatment.<sup>7</sup> <br><br>In contrast to other MAOIs, methylene blue has consistently enhanced blood pressure responses to norepinephrine or epinephrine, and/or decreased dose requirements of these drugs.<sup>8,9,10,11</sup> <br><br>Metaraminol product labeling states that MAO inhibitors have been reported to potentiate the effects of sympathomimetic amines.<sup>12,13</sup><br><br>Although not specifically investigated, the likely mechanism of this interaction is that MAO inhibitors inhibit the metabolism of endogenous sympathomimetic amines, leaving higher concentrations in the synapse. The exogenous administration of metaraminol may lead to overstimulation of the adrenergic receptors and an increase in the pressor response. The more consistent effects seen with methylene blue likely relate more to its inhibitory effects on inducible nitric oxide synthases and guanylate cyclase, and/or effects on other non-MAO systems.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Elis J, Laurence DR, Mattie H, Prichard BN. Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure. <i>Br Med J</i>. 1967;2(5544):75-78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6020852\">[PubMed 6020852]</a></p>\n<p>2. Horwitz D, Goldberg LI, Sjoerdsma A. Increased blood pressure responses to dopamine and norepinephrine produced by monoamine oxidase inhibitors in man. <i>J Lab Clin Med</i>. 1960;56:747-753. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13716048\">[PubMed 13716048]</a></p>\n<p>3. Barar FS, Boakes AJ, Benedikter LB, Laurence DR, Prichard BN, Teoh PC. Interactions between catecholamines and tricyclic and monoamine oxidase inhibitor antidepressive agents in man. <i>Br J Pharmacol</i>. 1971;43(2):472P-473P. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5158242\">[PubMed 5158242]</a></p>\n<p>4. Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN. Interactions between sympathomimetic amines and antidepressant agents in man. <i>Br Med J</i>. 1973;1:(5849):311-315. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4685619\">[PubMed 4685619]</a></p>\n<p>5. Cusson JR, Goldenberg E, Larochelle P. Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans. <i>J Clin Pharmacol</i>. 1991;31(5):462-467. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2050833\">[PubMed 2050833]</a></p>\n<p>6. Cuthbert MF, Vere DW. Potentiation of the cardiovascular effects of some catecholamines by a monoamine oxidase inhibitor. <i> Br J Pharmacol</i>. 1971;43(2):471P-472P. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5158241\">[PubMed 5158241]</a></p>\n<p>7. Bieck PR, Antonin KH. Monoamine oxidase inhibition by tranylcypromine: assessment in human volunteers. <i>Eur J Clin Pharmacol</i>. 1982;22(4):301-308. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7106165\">[PubMed 7106165]</a></p>\n<p>8. Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. <i>Crit Care Med</i>. 2001;29(10):1860-1867. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11588440\">[PubMed 11588440]</a></p>\n<p>9. Koelzow H, Gedney JA, Baumann J, Snook NJ, Bellamy MC. The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. <i>Anesth Analg</i>. 2002;94(4):824-829. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11916779\">[PubMed 11916779]</a></p>\n<p>10. Maslow AD, Stearns G, Butala P, Schwartz CS, Gough J, Singh AK. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. <i>Anesth Analg</i>. 2006;103(1):2-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16790616\">[PubMed 16790616]</a></p>\n<p>11. van Haren FM, Pickkers P, Foudraine N, Heemskerk S, Sleigh J, van der Hoeven JG. The effects of methylene blue infusion on gastric tonometry and intestinal fatty acid binding protein levels in septic shock patients. <i>J Crit Care</i>. 2010;25(2):358.e1-e7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20381302\">[PubMed 20381302]</a></p>\n<p>12. Metaraminol [summary of product characteristics]. Paignton UK: Torbay PMU; June 2015.</p>\n<p>13. Metaraminol [summary of product characteristics]. Sydney NSW, Australia: Montrose Pharma Pty Ltd; January 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10450":"<p><b>Title</b> Cardiac Glycosides / Metaraminol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Metaraminol may enhance the arrhythmogenic effect of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for the development of arrhythmias if metaraminol is combined with a cardiac glycoside.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin</p>\n</div> \n<p><b>Discussion</b> Metaraminol product labeling states that metaraminol should be used with caution in patients receiving cardiac glycosides, since the combination is capable of causing ectopic arrhythmic activity.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Metaraminol [summary of product characteristics]. Paignton UK: Torbay PMU; June 2015.</p>\n<p>2. Metaraminol [summary of product characteristics]. Sydney NSW, Australia: Montrose Pharma Pty Ltd; January 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10451":"<p><b>Title</b> Delavirdine / CarBAMazepine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: This combination is contraindicated according to the labeling for at least one brand (Equetro) but not in the labeling for at least one other brand (Tegretol).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Delavirdine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of carbamazepine with non-nucleoside reverse transcriptase inhibitors is contraindicated according to the labeling for at least one product (Equetro brand), but some products don't specifically contraindicate this combination (Tegretol brand).</p> \n<p><b>Discussion</b> The efavirenz AUC was reduced by an average of 34% with concurrent carbamazepine in a clinical study of healthy volunteers who received carbamazepine (400 mg daily for 21 days) with efavirenz (600 mg daily).<sup>1</sup> Similar changes were reported in carbamazepine-treated patients in efavirenz clinical trials.<sup>2</sup> The U.S. prescribing information for at least some carbamazepine products lists coadministration with non-nucleoside reverse transcriptase inhibitors (NNRTIs) as contraindicated due to a risk of decreased NNRTI concentrations,<sup>3,4</sup> but the labeling for some other carbamazepine products do not specifically contraindicate this combination.<sup>5</sup> Reduced NNRTI concentrations could lead to loss of virologic response and/or to the development of resistance. <br><br>The suspected primary mechanism of these interactions is carbamazepine induction of enzymes mediating metabolism of the NNRTIs (eg, CYP3A4 in all cases, likely also CYP2B6 in the case of efavirenz).<sup>3,6</sup> Single-dose carbamazepine did not immediately reduce nevirapine concentrations in one study, but one week later the median nevirapine concentrations were more than 50% lower in those who received carbamazepine.<sup>7</sup> Carbamazepine use was also associated with a 17-hour to 19-hour reduction in the nevirapine half-life and another study of single-dose nevirapine pharmacokinetics.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ji P, Damle B, Xie J, Unger SE, Grasela DM, Kaul S. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. <i>J Clin Pharmacol</i>. 2008;48(8):948-956. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18519918\">[PubMed 18519918]</a></p>\n<p>2. Zhu M, Kaul S, Nandy P, Grasela DM, Pfister M. Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. <i>Antimicrob Agents Chemother</i>. 2009;53(6):2346-2353. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19223624\">[PubMed 19223624]</a></p>\n<p>3. Equetro (carbamazepine) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; November 2012.</p>\n<p>4. Carbatrol (carbamazepine) [prescribing information]. Wayne, PA: Shire US Inc.; March 2013.</p>\n<p>5. Tegretol (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2015.</p>\n<p>6. Desta Z, Saussele T, Ward B, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. <i>Pharmacogenomics</i>. 2007;8(6):547-558. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17559344\">[PubMed 17559344]</a></p>\n<p>7. Muro EP, Fillekes Q, Kisanga ER, et al. Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention. <i>J Acquir Immune Defic Syndr</i>. 2012;59(3):266-273. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22134145\">[PubMed 22134145]</a></p>\n<p>8. L'homme RF, Dijkema T, van der Ven AJ, Burger DM. Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. <i>J Acquir Immune Defic Syndr</i>. 2006;43(2):193-196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16940857\">[PubMed 16940857]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10452":"<p><b>Title</b> Efavirenz / CarBAMazepine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: This combination is contraindicated according to the labeling for at least one brand (Equetro) but not in the labeling for at least one other brand (Tegretol).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of CarBAMazepine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of carbamazepine with non-nucleoside reverse transcriptase inhibitors is contraindicated according to the labeling for at least one product (Equetro brand), but some products don't specifically contraindicate this combination (Tegretol brand).</p> \n<p><b>Discussion</b> The efavirenz AUC was reduced by an average of 34% with concurrent carbamazepine in a clinical study of healthy volunteers who received carbamazepine (400 mg daily for 21 days) with efavirenz (600 mg daily).<sup>1</sup> Similar changes were reported in carbamazepine-treated patients in efavirenz clinical trials.<sup>2</sup> The U.S. prescribing information for at least some carbamazepine products lists coadministration with non-nucleoside reverse transcriptase inhibitors (NNRTIs) as contraindicated due to a risk of decreased NNRTI concentrations,<sup>3,4</sup> but the labeling for some other carbamazepine products do not specifically contraindicate this combination.<sup>5</sup> Reduced NNRTI concentrations could lead to loss of virologic response and/or to the development of resistance. <br><br>The suspected primary mechanism of these interactions is carbamazepine induction of enzymes mediating metabolism of the NNRTIs (eg, CYP3A4 in all cases, likely also CYP2B6 in the case of efavirenz).<sup>3,6</sup> Single-dose carbamazepine did not immediately reduce nevirapine concentrations in one study, but one week later the median nevirapine concentrations were more than 50% lower in those who received carbamazepine.<sup>7</sup> Carbamazepine use was also associated with a 17-hour to 19-hour reduction in the nevirapine half-life and another study of single-dose nevirapine pharmacokinetics.<sup>8</sup> Carbamazepine AUC was also reduced 27% by efavirenz in one study, likely due to enzyme induction by both drugs, while carbamazepine-10,11-epoxide pharmacokinetic variables were not affected.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ji P, Damle B, Xie J, Unger SE, Grasela DM, Kaul S. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. <i>J Clin Pharmacol</i>. 2008;48(8):948-956. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18519918\">[PubMed 18519918]</a></p>\n<p>2. Zhu M, Kaul S, Nandy P, Grasela DM, Pfister M. Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. <i>Antimicrob Agents Chemother</i>. 2009;53(6):2346-2353. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19223624\">[PubMed 19223624]</a></p>\n<p>3. Equetro (carbamazepine) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; November 2012.</p>\n<p>4. Carbatrol (carbamazepine) [prescribing information]. Wayne, PA: Shire US Inc.; March 2013.</p>\n<p>5. Tegretol (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2015.</p>\n<p>6. Desta Z, Saussele T, Ward B, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. <i>Pharmacogenomics</i>. 2007;8(6):547-558. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17559344\">[PubMed 17559344]</a></p>\n<p>7. Muro EP, Fillekes Q, Kisanga ER, et al. Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention. <i>J Acquir Immune Defic Syndr</i>. 2012;59(3):266-273. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22134145\">[PubMed 22134145]</a></p>\n<p>8. L'homme RF, Dijkema T, van der Ven AJ, Burger DM. Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. <i>J Acquir Immune Defic Syndr</i>. 2006;43(2):193-196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16940857\">[PubMed 16940857]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10453":"<p><b>Title</b> Etravirine / CarBAMazepine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: This combination is contraindicated according to the labeling for at least one brand (Equetro) but not in the labeling for at least one other brand (Tegretol).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Etravirine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of carbamazepine with non-nucleoside reverse transcriptase inhibitors is contraindicated according to the labeling for at least one product (Equetro brand), but some products don't specifically contraindicate this combination (Tegretol brand).</p> \n<p><b>Discussion</b> The efavirenz AUC was reduced by an average of 34% with concurrent carbamazepine in a clinical study of healthy volunteers who received carbamazepine (400 mg daily for 21 days) with efavirenz (600 mg daily).<sup>1</sup> Similar changes were reported in carbamazepine-treated patients in efavirenz clinical trials.<sup>2</sup> The U.S. prescribing information for at least some carbamazepine products lists coadministration with non-nucleoside reverse transcriptase inhibitors (NNRTIs) as contraindicated due to a risk of decreased NNRTI concentrations,<sup>3,4</sup> but the labeling for some other carbamazepine products do not specifically contraindicate this combination.<sup>5</sup> Reduced NNRTI concentrations could lead to loss of virologic response and/or to the development of resistance. <br><br>The suspected primary mechanism of these interactions is carbamazepine induction of enzymes mediating metabolism of the NNRTIs (eg, CYP3A4 in all cases, likely also CYP2B6 in the case of efavirenz).<sup>3,6</sup> Single-dose carbamazepine did not immediately reduce nevirapine concentrations in one study, but one week later the median nevirapine concentrations were more than 50% lower in those who received carbamazepine.<sup>7</sup> Carbamazepine use was also associated with a 17-hour to 19-hour reduction in the nevirapine half-life and another study of single-dose nevirapine pharmacokinetics.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ji P, Damle B, Xie J, Unger SE, Grasela DM, Kaul S. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. <i>J Clin Pharmacol</i>. 2008;48(8):948-956. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18519918\">[PubMed 18519918]</a></p>\n<p>2. Zhu M, Kaul S, Nandy P, Grasela DM, Pfister M. Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. <i>Antimicrob Agents Chemother</i>. 2009;53(6):2346-2353. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19223624\">[PubMed 19223624]</a></p>\n<p>3. Equetro (carbamazepine) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; November 2012.</p>\n<p>4. Carbatrol (carbamazepine) [prescribing information]. Wayne, PA: Shire US Inc.; March 2013.</p>\n<p>5. Tegretol (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2015.</p>\n<p>6. Desta Z, Saussele T, Ward B, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. <i>Pharmacogenomics</i>. 2007;8(6):547-558. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17559344\">[PubMed 17559344]</a></p>\n<p>7. Muro EP, Fillekes Q, Kisanga ER, et al. Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention. <i>J Acquir Immune Defic Syndr</i>. 2012;59(3):266-273. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22134145\">[PubMed 22134145]</a></p>\n<p>8. L'homme RF, Dijkema T, van der Ven AJ, Burger DM. Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. <i>J Acquir Immune Defic Syndr</i>. 2006;43(2):193-196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16940857\">[PubMed 16940857]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10454":"<p><b>Title</b> Nevirapine / CarBAMazepine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: This combination is contraindicated according to the labeling for at least one brand (Equetro) but not in the labeling for at least one other brand (Tegretol).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Nevirapine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of carbamazepine with non-nucleoside reverse transcriptase inhibitors is contraindicated according to the labeling for at least one product (Equetro brand), but some products don't specifically contraindicate this combination (Tegretol brand).</p> \n<p><b>Discussion</b> The efavirenz AUC was reduced by an average of 34% with concurrent carbamazepine in a clinical study of healthy volunteers who received carbamazepine (400 mg daily for 21 days) with efavirenz (600 mg daily).<sup>1</sup> Similar changes were reported in carbamazepine-treated patients in efavirenz clinical trials.<sup>2</sup> The U.S. prescribing information for at least some carbamazepine products lists coadministration with non-nucleoside reverse transcriptase inhibitors (NNRTIs) as contraindicated due to a risk of decreased NNRTI concentrations,<sup>3,4</sup> but the labeling for some other carbamazepine products do not specifically contraindicate this combination.<sup>5</sup> Reduced NNRTI concentrations could lead to loss of virologic response and/or to the development of resistance. <br><br>The suspected primary mechanism of these interactions is carbamazepine induction of enzymes mediating metabolism of the NNRTIs (eg, CYP3A4 in all cases, likely also CYP2B6 in the case of efavirenz).<sup>3,6</sup> Single-dose carbamazepine did not immediately reduce nevirapine concentrations in one study, but one week later the median nevirapine concentrations were more than 50% lower in those who received carbamazepine.<sup>7</sup> Carbamazepine use was also associated with a 17-hour to 19-hour reduction in the nevirapine half-life and another study of single-dose nevirapine pharmacokinetics.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ji P, Damle B, Xie J, Unger SE, Grasela DM, Kaul S. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. <i>J Clin Pharmacol</i>. 2008;48(8):948-956. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18519918\">[PubMed 18519918]</a></p>\n<p>2. Zhu M, Kaul S, Nandy P, Grasela DM, Pfister M. Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. <i>Antimicrob Agents Chemother</i>. 2009;53(6):2346-2353. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19223624\">[PubMed 19223624]</a></p>\n<p>3. Equetro (carbamazepine) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; November 2012.</p>\n<p>4. Carbatrol (carbamazepine) [prescribing information]. Wayne, PA: Shire US Inc.; March 2013.</p>\n<p>5. Tegretol (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2015.</p>\n<p>6. Desta Z, Saussele T, Ward B, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. <i>Pharmacogenomics</i>. 2007;8(6):547-558. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17559344\">[PubMed 17559344]</a></p>\n<p>7. Muro EP, Fillekes Q, Kisanga ER, et al. Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention. <i>J Acquir Immune Defic Syndr</i>. 2012;59(3):266-273. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22134145\">[PubMed 22134145]</a></p>\n<p>8. L'homme RF, Dijkema T, van der Ven AJ, Burger DM. Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. <i>J Acquir Immune Defic Syndr</i>. 2006;43(2):193-196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16940857\">[PubMed 16940857]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10455":"<p><b>Title</b> Rilpivirine / CarBAMazepine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: This combination is contraindicated according to the labeling for at least one brand (Equetro) but not in the labeling for at least one other brand (Tegretol).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Rilpivirine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of carbamazepine with non-nucleoside reverse transcriptase inhibitors is contraindicated according to the labeling for at least one product (Equetro brand), but some products don't specifically contraindicate this combination (Tegretol brand).</p> \n<p><b>Discussion</b> The efavirenz AUC was reduced by an average of 34% with concurrent carbamazepine in a clinical study of healthy volunteers who received carbamazepine (400 mg daily for 21 days) with efavirenz (600 mg daily).<sup>1</sup> Similar changes were reported in carbamazepine-treated patients in efavirenz clinical trials.<sup>2</sup> The U.S. prescribing information for at least some carbamazepine products lists coadministration with non-nucleoside reverse transcriptase inhibitors (NNRTIs) as contraindicated due to a risk of decreased NNRTI concentrations,<sup>3,4</sup> but the labeling for some other carbamazepine products do not specifically contraindicate this combination.<sup>5</sup> Reduced NNRTI concentrations could lead to loss of virologic response and/or to the development of resistance. <br><br>The suspected primary mechanism of these interactions is carbamazepine induction of enzymes mediating metabolism of the NNRTIs (eg, CYP3A4 in all cases, likely also CYP2B6 in the case of efavirenz).<sup>3,6</sup> Single-dose carbamazepine did not immediately reduce nevirapine concentrations in one study, but one week later the median nevirapine concentrations were more than 50% lower in those who received carbamazepine.<sup>7</sup> Carbamazepine use was also associated with a 17-hour to 19-hour reduction in the nevirapine half-life and another study of single-dose nevirapine pharmacokinetics.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ji P, Damle B, Xie J, Unger SE, Grasela DM, Kaul S. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. <i>J Clin Pharmacol</i>. 2008;48(8):948-956. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18519918\">[PubMed 18519918]</a></p>\n<p>2. Zhu M, Kaul S, Nandy P, Grasela DM, Pfister M. Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. <i>Antimicrob Agents Chemother</i>. 2009;53(6):2346-2353. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19223624\">[PubMed 19223624]</a></p>\n<p>3. Equetro (carbamazepine) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; November 2012.</p>\n<p>4. Carbatrol (carbamazepine) [prescribing information]. Wayne, PA: Shire US Inc.; March 2013.</p>\n<p>5. Tegretol (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2015.</p>\n<p>6. Desta Z, Saussele T, Ward B, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. <i>Pharmacogenomics</i>. 2007;8(6):547-558. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17559344\">[PubMed 17559344]</a></p>\n<p>7. Muro EP, Fillekes Q, Kisanga ER, et al. Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention. <i>J Acquir Immune Defic Syndr</i>. 2012;59(3):266-273. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22134145\">[PubMed 22134145]</a></p>\n<p>8. L'homme RF, Dijkema T, van der Ven AJ, Burger DM. Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. <i>J Acquir Immune Defic Syndr</i>. 2006;43(2):193-196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16940857\">[PubMed 16940857]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10456":"<p><b>Title</b> Bezafibrate / Mizoribine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Mizoribine may enhance the adverse/toxic effect of Bezafibrate. Specifically, the risk for muscle toxicities may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased bezafibrate muscle toxicities (ie, myalgias, myopathy, rhabdomyolysis) if combined with mizoribine.</p> \n<p><b>Discussion</b> One case report describes a 50-year-old woman who had been stable on bezafibrate therapy (400 mg daily) for more than 1 year.<sup>1</sup> Two weeks after the initiation of mizoribine (150 mg daily) for the treatment of rheumatoid arthritis, she was hospitalized with new onset myalgia, malaise, and weakness.<sup>1</sup> Her creatine kinase was elevated (4,237 units/L) and she had signs of acute renal failure (serum creatinine 2.73 mg/dL and blood urea nitrogen 64 mg/dL).<sup>1</sup> Two days after the discontinuation of bezafibrate and mizoribine and treatment with intravenous hydration (sodium chloride and sodium bicarbonate), her symptoms resolved and her laboratory values normalized.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but there is evidence that mizoribine inhibition of OAT1 and OAT3, transporters involved in the active renal tubular secretion of bezafibrate, may play a role.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Morimoto S, Fujioka Y, Tsutsumi C, et al. Mizoribine-induced rhabdomyolysis in a rheumatoid arthritis patient receiving bezafibrate treatment. <i>Am J Med Sci</i>. 2005;329(4):211-213. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15832106\">[PubMed 15832106]</a></p>\n<p>2. Feng Y, Wang C, Liu Q, et al. Bezafibrate-mizoribine interaction: Involvement of organic anion transporters OAT1 and OAT3 in rats. <i>Eur J Pharm Sci</i>. 2016;81:119-128. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26474691\">[PubMed 26474691]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10457":"<p><b>Title</b> Cabozantinib / MRP2 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of increased cabozantinib adverse effects or toxicity with use of this combination.</p>\n<div>\n <p><b>MRP2 Inhibitors Interacting Members</b> Abacavir, Adefovir, Cidofovir, Enzalutamide, Furosemide, LamiVUDine, Nevirapine, Probenecid, Ritonavir, Saquinavir, Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate</p>\n</div> \n<p><b>Discussion</b> The prescribing information for cabozantinib cautions that concurrent use of MRP2 (aka ABCC2) inhibitors together with cabozantinib may increase the exposure to cabozantinib, possibly increasing the risk for cabozantinib-related toxicities, although the clinical significance of this potential interaction is uncertain.<sup>1,2</sup> This warning appears based on in vitro data showing that cabozantinib is a substrate for MRP2, suggesting that MRP2 inhibitors may inhibit the MRP2-mediated efflux of cabozantinib, leading to increased cabozantinib concentrations and effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cometriq (cabozantinib) [prescribing information]. South San Francisco, CA: Exelixis, Inc.; May 2016.</p>\n<p>2. Cabometyx (cabozantinib) [prescribing information]. South San Francisco, CA: Exelixis, Inc.; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10458":"<p><b>Title</b> Obeticholic Acid / Bile Acid Sequestrants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the serum concentration of Obeticholic Acid. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer obeticholic acid at least 4 hours before or at least 4 hours after the administration of bile acid sequestrants.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin, Colesevelam, Colestipol</p>\n</div> \n<p><b>Discussion</b> Obeticholic acid prescribing information states that because bile acid sequestrants adsorb and reduce bile acid absorption, they may reduce the absorption, systemic exposure, and efficacy of obeticholic acid, a drug that relies on enterohepatic recirculation for systemic exposure.<sup>1</sup> Administer obeticholic acid at least 4 hours before or at least 4 hours after the administration of bile acid sequestrants.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ocaliva (obeticholic acid) [prescribing information]. New York, NY: Intercept Pharmaceuticals Inc; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10459":"<p><b>Title</b> Warfarin / Obeticholic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Obeticholic Acid may diminish the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased warfarin effects (eg, decreased INR) if combined with obeticholic acid.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the obeticholic acid prescribing information, coadministration of obeticholic acid (10 mg daily) and warfarin (25 mg single dose) increased the S-warfarin exposure 13%, but resulted in an 11% decrease in the maximum INR.<sup>1</sup><br><br>Obeticholic prescribing information states that due to decreased INR following the coadministration of obeticholic acid and warfarin, INR monitoring should be increased when these agents are combined.<sup>1</sup><br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ocaliva (obeticholic acid) [prescribing information]. New York, NY: Intercept Pharmaceuticals Inc; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10460":"<p><b>Title</b> Omeprazole / Obeticholic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Obeticholic Acid may increase the serum concentration of Omeprazole. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the obeticholic acid prescribing information, obeticholic acid (10 mg daily) increased the omeprazole (20 mg single dose) AUC and maximum serum concentration 32% and 33%, respectively.<sup>1</sup> Concomitant administration of omeprazole (20 mg once daily) with obeticholic acid (10 mg daily) resulted in a less than 1.2-fold increase in obeticholic acid exposure.<sup>1</sup> The clinical significance of these changes appears minimal.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ocaliva (obeticholic acid) [prescribing information]. New York, NY: Intercept Pharmaceuticals Inc; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10461":"<p><b>Title</b> CYP1A2 Substrates (High risk with Inhibitors) / Obeticholic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Obeticholic Acid may increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects/toxicities of CYP1A2 substrates if combined with obeticholic acid. This interaction is likely of greater clinical importance with CYP1A2 substrates that have a narrow therapeutic index (eg, tizanidine, theophylline).</p>\n<div>\n <p><b>CYP1A2 Substrates (High risk with Inhibitors) Interacting Members</b> Acebrophylline, Acenocoumarol, Agomelatine, Alosetron, Aminophylline, Asenapine, Bromazepam, Caffeine, ClomiPRAMINE, CloZAPine, Cyclobenzaprine, Dacarbazine, DULoxetine, Flutamide, FluvoxaMINE, Kola Nut, Lidocaine (Systemic), Lidocaine (Topical), Melatonin, Mexiletine, Mirtazapine, OLANZapine, Pimozide, Pirfenidone, Pomalidomide, Propranolol, Ramelteon, Ramosetron, Rasagiline, ROPINIRole, Ropivacaine, Stiripentol, Tasimelteon, Theophylline, Thiothixene, TiZANidine, Trifluoperazine</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the obeticholic acid prescribing information, obeticholic acid (10 mg daily) increased the CYP1A2 substrate caffeine (200 mg single dose) AUC and maximum serum concentration 42% and 6%, respectively.<sup>1</sup> <br><br>Obeticholic acid may increase the exposure to concomitant drugs that are CYP1A2 substrates. Monitoring for increased effects of CYP1A2 substrates with a narrow therapeutic index (eg, theophylline, tizanidine) is recommended when coadministered with obeticholic acid.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ocaliva (obeticholic acid) [prescribing information]. New York, NY: Intercept Pharmaceuticals Inc; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10462":"<p><b>Title</b> Warfarin / Nevirapine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nevirapine may diminish the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased warfarin effects (eg, decreased INR) if nevirapine is initiated in a warfarin treated patient. Conversely, monitor for increased warfarin effects (eg, increased INR, bleeding) if nevirapine is discontinued in a warfarin treated patient.</p> \n<p><b>Discussion</b> Two published reports describe 4 patients who experienced a potential interaction between warfarin and nevirapine.<sup>1,2</sup> A 39-year-old man receiving nevirapine required warfarin 20 mg daily to achieve a therapeutic INR.<sup>1</sup> After discontinuation of nevirapine, his warfarin dose had to be reduced to just 12.5 mg daily to maintain a therapeutic INR.<sup>1</sup> A 38-year-old man stable on warfarin therapy (2.5 mg daily) required a doubling of his warfarin dose (5 mg daily) to achieved a therapeutic INR after initiation of nevirapine.<sup>2</sup> Two additional nevirapine treated patients received increasing doses of warfarin but were unable to achieve a therapeutic INR until nevirapine was discontinued.<sup>2</sup><br><br>The mechanism of this interaction has not been investigated, but nevirapine induction of CYP3A4, an enzyme responsible for R-warfarin metabolism, may play a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fulco PP, Zingone MM, Higginson RT. Possible antiretroviral therapy-warfarin drug interaction. <i>Pharmacotherapy</i>. 2008;28(7):945-949. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18576910\">[PubMed 18576910]</a></p>\n<p>2. Dionisio D, Mininni S, Bartolozzi D, Esperti F, Vivarelli A, Leoncini F. Need for increased dose of warfarin in HIV positive patients taking nevirapine. <i>AIDS</i>. 2001;15(2):277-278. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11216940\">[PubMed 11216940]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10463":"<p><b>Title</b> Vaccines (Live) / Daclizumab</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Daclizumab may enhance the adverse/toxic effect of Vaccines (Live). Daclizumab may diminish the therapeutic effect of Vaccines (Live). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Whenever possible, patients should receive all recommended live vaccinations prior to initiation of daclizumab therapy. Live vaccine administration should generally be avoided in patients with impaired immune function due to the risk of developing a clinical infection from the live vaccine. Inadequate immune response to the vaccine may also occur during treatement with daclizumab. Live vaccines should be avoided during treatment with daclizumab and for 4 months after cessation of daclizumab therapy.<br><br>Note that some products (eg, both seasonal and H1N1 influenza virus vaccines) are available as either a live or inactivated product; this interaction pertains only to the live form of these vaccines.</p>\n<div>\n <p><b>Vaccines (Live) Interacting Members</b> Adenovirus (Types 4, 7) Vaccine, BCG Vaccine (Immunization), Cholera Vaccine, Influenza Virus Vaccine (Live/Attenuated), Japanese Encephalitis Virus Vaccine (Live/Attenuated), Measles, Mumps, and Rubella Virus Vaccine, Measles, Mumps, Rubella, and Varicella Virus Vaccine, Poliovirus Vaccine (Live/Bivalent/Oral), Poliovirus Vaccine (Live/Trivalent/Oral), Rotavirus Vaccine, Smallpox Vaccine Live, Typhoid Vaccine, Varicella Virus Vaccine, Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated)</p>\n</div> \n<p><b>Discussion</b> Although immunization with live vaccines during treatment with daclizumab has not been evaluated, a case report describes a patient who developed a vaccinial infection due to smallpox vaccine when administered while under treatment with methotrexate (15 mg/day) for psoriasis.<sup>1</sup> Animals studies have confirmed the increased susceptibility to vaccinial infections when receiving immunosuppressants.<sup>2</sup> Other reports of severe complications following administration of live vaccines to patients with disease-related compromised immune function further emphasize this potential risk.<sup>3,4,5,6,7,8,9,10,11</sup> While receiving immunosuppressant agents such as daclizumab, patients may lack adequate protection against the live organism vaccine.<br><br>General recommendations of the Advisory Committee on Immunization Practices (ACIP) states that live-attenuated vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy.<sup>12</sup> Daclizumab prescribing information states that live vaccines should be avoided during treatment with daclizumab and for 4 months after cessation of daclizumab therapy.<sup>13</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Allison J. Methotrexate and smallpox vaccination. <i>Lancet</i>. 1968;2(7580):1250. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4177233\">[PubMed 4177233]</a></p>\n<p>2. Rosenbaum EH, Cohen RA, Glatstein HR. Vaccination of a patient receiving immunosuppressive therapy for lymphosarcoma. <i>JAMA</i>. 1966;198(7):737-740. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5953328\">[PubMed 5953328]</a></p>\n<p>3. Sixbey JW. Routine immunizations and the immunosuppressed child. <i>Adv Pediatr Infect Dis</i>. 1987;2:79-114. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3331284\">[PubMed 3331284]</a></p>\n<p>4. Wright PF, Hatch MH, Kasselberg AG, Lowry SP, Wadlington WB, Karzon DT. Vaccine-associated poliomyelitis in a child with sex-linked agammaglobulinemia. <i>J Pediatr</i>. 1977;91(3):408-412. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=197220\">[PubMed 197220]</a></p>\n<p>5. Wyatt HV. Poliomyelitis in hypogammaglobulinemics. <i>J Infect Dis</i>. 1973;128(6):802-806. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4765357\">[PubMed 4765357]</a></p>\n<p>6. Davis LE, Bodian D, Price D, Butler IJ, Vickers JH. Chronic progressive poliomyelitis secondary to vaccination of an immunodeficient child. <i>N Engl J Med</i>. 1977;297(5):241-245. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=195206\">[PubMed 195206]</a></p>\n<p>7. Centers for Disease Control (CDC). Disseminated <i>Mycobacterium bovis</i> infection from BCG vaccination of a patient with acquired immunodeficiency syndrome. <i>MMWR Morb Mortal Wkly Rep</i>. 1985;34(16):227-228. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3920493\">[PubMed 3920493]</a></p>\n<p>8. Ninane J, Grymonprez A, Burtonboy G, Francois A, Cornu G. Disseminated BCG in HIV infection. <i>Arch Dis Child</i>. 1988;63(10):1268-1269. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3196057\">[PubMed 3196057]</a></p>\n<p>9. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. <i>N Engl J Med</i>. 1987;316(11):673-676. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3821799\">[PubMed 3821799]</a></p>\n<p>10. Centers for Disease Control and Prevention (CDC). Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. <i>MMWR Morb Mortal Wkly Rep</i>. 1996;45(28):603-606. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8676852\">[PubMed 8676852]</a></p>\n<p>11. Costa E, Buxton J, Brown J, Templeton KE, Breuer J, Johannessen I. Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient [published online May 4, 2016]. <i>BMJ Case Rep</i>. doi: 10.1136/bcr-2015-212688. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27147629\">[PubMed 27147629]</a></p>\n<p>12. National Center for Immunization and Respiratory Diseases. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2011;60(2):1-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21293327\">[PubMed 21293327]</a></p>\n<p>13. Zinbryta (daclizumab) [prescribing information]. North Chicago, IL: AbbVie Inc; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10464":"<p><b>Title</b> AtorvaSTATin / SITagliptin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> SITagliptin may enhance the adverse/toxic effect of AtorvaSTATin. Specifically, the risk for rhabdomyolysis may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor closely for evidence of rhabdomyolysis or other toxicities with use of this combination. Advise patients to promptly report any signs or symptoms of muscle-related toxicity.</p> \n<p><b>Discussion</b> Several case reports describe patients who developed rhabdomyolysis days to months after the addition of sitagliptin to ongoing treatment with an HMG-CoA reductase inhibitor (aka “statin”). All four published case reports involve patients who were 60 to 76 years-of-age, with the sitagliptin added between approximately one week and six months prior to patient presentation.<sup>1,2,3,4</sup> Two cases involve atorvastatin,<sup>1,2</sup> with one each involving simvastatin and lovastatin.<sup>3,4</sup> Although each report implicates a sitagliptin-statin interaction as the likely, or at least a plausible, culprit behind the rhabdomyolysis development, each case featured other possible contributing factors, such as concurrent use of CYP3A4 inhibitors, older patient age, and/or use of moderate to high statin doses. The presence of these factors, combined with the lack of a clear, biologically plausible mechanism by which sitagliptin would increase the risk of statin-related rhabdomyolysis, raise questions regarding the precise role of sitagliptin as a contributing factor in these cases.<br><br>Authors of these case reports have suggested possible inhibition of CYP3A4 and/or p-glycoprotein, or sitagliptin-mediated impairments in renal function as explanations for the potential interactions.<sup>1,2,3,4</sup> Sitagliptin had no significant impact on simvastatin pharmacokinetics in one controlled study, increasing the AUC of the active simvastatin acid by only 12%.<sup>5</sup> While selected, higher-risk individuals may experience a greater-than-average interaction between these agents, possibly explaining these few observed cases, it seems at least equally plausible that other factors, besides a sitagliptin-statin interaction, account for the toxicity observed in these cases.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Khan MW, Kurian S, Bishnoi R. Acute-onset rhabdomyolysis secondary to sitagliptin and atorvastatin interaction. <i>Int J Gen Med</i>. 2016;9:103-106. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27199569\">[PubMed 27199569]</a></p>\n<p>2. Bhome R, Penn H. Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction. <i>Diabet Med</i>. 2012;29(5):693-694. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22023482\">[PubMed 22023482]</a></p>\n<p>3. DiGregorio RV, Pasikhova Y. Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction. <i>Pharmacotherapy</i>. 2009;29(3):352-356. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19249953\">[PubMed 19249953]</a></p>\n<p>4. Kao DP, Kohrt HE, Kugler J. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. <i>Diabet Med</i>. 2008;25(10):1229-1230. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19046202\">[PubMed 19046202]</a></p>\n<p>5. Bergman AJ, Cote J, Maes A, et al. Effect of sitagliptin on the pharmacokinetics of simvastatin. <i>J Clin Pharmacol</i>. 2009;49(4):483-488. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19204138\">[PubMed 19204138]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10465":"<p><b>Title</b> GuaiFENesin / Butamirate</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Butamirate may enhance the adverse/toxic effect of GuaiFENesin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Butamirate product labeling states that because the cough reflex is inhibited by butamirate, the concomitant administration of expectorants (ie, guaifenesin) should be avoided because this may lead to stagnation of mucus in the respiratory tract, increasing the risk of bronchospasm and respiratory tract infections.<sup>1,2</sup> However, no clinical studies have been published that describe this potential interaction and numerous combination products are available that contain a cough suppressant and an expectorant.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Butamirate syrup [summary of product characteristics]. Hafnarfjorour, Iceland: Actavis Group PTC ehf; April 2015.</p>\n<p>2. NeoCitran Antitussive (butamirate) drops, syrup, and tablets [summary of product characteristics]. Risch, Switzerland: Novartis Consumer Health SA; March 2013.</p>\n<p>3. Mucinex DM (guaifenesin and dextromethorphan) [prescribing information]. Fort Worth, TX: Adams Respiratory Therapeutics; September 2007.</p>\n<p>4. Flowtuss (hydrocodone and guaifenesin) [prescribing information]. Dallas, TX: Cintex Services LLC; May 2015.</p>\n<p>5. Obredon (hydrocodone and guaifenesin) [prescribing information]. Fort Worth, TX: Sovereign Pharmaceuticals LLC; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10466":"<p><b>Title</b> Lomitapide / Ciprofloxacin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ciprofloxacin (Systemic) may increase the serum concentration of Lomitapide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The lomitapide U.S. prescribing information lists ciprofloxacin as a moderate CYP3A4 inhibitor, with which concurrent use of lomitapide is contraindicated. However, available data suggest ciprofloxacin is actually a weak CYP3A4 inhibitor, and according to the lomitapide labeling, the recommendation is that patients taking lomitapide 10 mg daily or more should decrease the dose of lomitapide by half when used in combination with any weak CYP3A4 inhibitor and that the lomitapide dose may then be up-titrated to a maximum adult dose of 30 mg daily (patients taking lomitapide 5 mg daily may continue the same dosage).</p> \n<p><b>Discussion</b> The lomitapide prescribing information lists ciprofloxacin as an example of a moderate CYP3A4 inhibitor,<sup>1</sup> but available data suggests ciprofloxacin is more likely only a weak inhibitor of CYP3A4. While ciprofloxacin 500 mg did demonstrate moderate level CYP3A4 inhibition in one study by increasing the AUC of the CYP3A4 substrate sildenafil by 2.1-fold,<sup>2</sup> only weak level CYP3A4 inhibition was reported in two other studies with CYP3A4 substrates, where ciprofloxacin 500 mg was associated with 1.5- and 1.8-fold increases in carbamazepine and itraconazole AUC, respectively.<sup>3,4</sup> This distinction is an important one as lomitapide is contraindicated with moderate CYP3A4 inhibitors, while lomitapide dose adjustments are recommended with weak CYP3A4 inhibitors.<sup>1</sup><br><br>In a clinical study summarized in the lomitapide prescribing information, coadministration of the strong CYP3A4 inhibitor ketoconazole (200 mg twice daily for 9 days) increased lomitapide (60 mg daily) maximum concentration and AUC by roughly 15- and 27-fold, respectively.<sup>1</sup> While the potential interaction between lomitapide and moderate CYP3A4 inhibitors has not been studied, concomitant use is contraindicated per lomitapide U.S. prescribing information due to the potential for increases in lomitapide exposure.<sup>1</sup><br><br>The lomitapide AUC was increased by approximately 2- and 1.3-fold, respectively, in a clinical study where subjects received atorvastatin 80 mg/day either administered with or separated by 12 hours from lomitapide (20 mg/day).<sup>5</sup><br><br>The likely mechanism for these interactions is inhibition of the CYP3A4-mediated metabolism of lomitapide by strong, moderate, or weak CYP3A4 inhibitors. The lomitapide prescribing information recommends dose reductions when used together with weak CYP3A4 inhibitors, while concomitant use with moderate or strong CYP3A4 inhibitors is contraindicated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Juxtapid (lomitapide) [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; March 2016.</p>\n<p>2. Hedaya MA, El-Afify DR, El-Maghraby GM. The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. <i>Biopharm Drug Dispos</i>. 2006;27(2):103-110. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16372380\">[PubMed 16372380]</a></p>\n<p>3. Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. <i>Pak J Pharm Sci</i>. 2011;24(1):63-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21190921\">[PubMed 21190921]</a></p>\n<p>4. Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. <i>Biopharm Drug Dispos</i>. 2011;32(3):168-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21360715\">[PubMed 21360715]</a></p>\n<p>5. Patel G, King A, Dutta S, et al. Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects. <i>J Clin Pharmacol</i>. 2016;56(1):47-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26120010\">[PubMed 26120010]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10467":"<p><b>Title</b> Lomitapide / Nilotinib</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nilotinib may increase the serum concentration of Lomitapide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The lomitapide U.S. prescribing information lists nilotinib as a weak CYP3A4 inhibitor, for which the recommendation is that patients taking lomitapide 10 mg daily or more should decrease the dose of lomitapide by half when used in combination with any weak CYP3A4 inhibitor and that the lomitapide dose may then be up-titrated to a maximum adult dose of 30 mg daily (patients taking lomitapide 5 mg daily may continue the same dosage). However, available data suggest nilotinib is actually a moderate CYP3A4 inhibitor, and according to the lomitapide labeling, the use of lomitapide together with any moderate CYP3A4 inhibitor is contraindicated.</p> \n<p><b>Discussion</b> The lomitapide prescribing information lists nilotinib as an example of a weak CYP3A4 inhibitor,<sup>1</sup> but nilotinib appears to be a moderate inhibitor of CYP3A4 based on data showing that multi-dose nilotinib was associated with a 2.6-fold increase in the AUC of midazolam, which is a sensitive CYP3A4 substrate.<sup>2,3</sup> This distinction is an important one as lomitapide is contraindicated with moderate CYP3A4 inhibitors, while lomitapide dose adjustments are recommended with weak CYP3A4 inhibitors.<sup>1</sup><br><br>In a clinical study summarized in the lomitapide prescribing information, coadministration of the strong CYP3A4 inhibitor ketoconazole (200 mg twice daily for 9 days) increased lomitapide (60 mg daily) maximum concentration and AUC by roughly 15- and 27-fold, respectively.<sup>1</sup> While the potential interaction between lomitapide and moderate CYP3A4 inhibitors has not been studied, concomitant use is contraindicated per lomitapide U.S. prescribing information due to the potential for increases in lomitapide exposure.<sup>1</sup><br><br>The lomitapide AUC was increased by approximately 2- and 1.3-fold, respectively, in a clinical study where subjects received atorvastatin 80 mg/day either administered with or separated by 12 hours from lomitapide (20 mg/day).<sup>1</sup><br><br>The likely mechanism for these interactions is inhibition of the CYP3A4-mediated metabolism of lomitapide by strong, moderate, or weak CYP3A4 inhibitors. The lomitapide prescribing information recommends dose reductions when used together with weak CYP3A4 inhibitors, while concomitant use with moderate or strong CYP3A4 inhibitors is contraindicated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Juxtapid (lomitapide) [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; May 2015.</p>\n<p>2. Zhang H, Sheng J, Ko JH, et al. Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam. <i>J Clin Pharmacol</i>. 2015;55(4):401-408. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25418605\">[PubMed 25418605]</a></p>\n<p>3. Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10468":"<p><b>Title</b> Warfarin / Cabozantinib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cabozantinib may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor closely for evidence of an excessive anticoagulant response to warfarin with concurrent cabozantinib, including consideration of monitoring INR more frequently.</p> \n<p><b>Discussion</b> A case report describes a 64-year-old man, previously stable on warfarin therapy, who presented with an INR of 9.7 two weeks after starting cabozantinib 140 mg/day for treatment of metastatic renal cell carcinoma.<sup>1</sup> His INR decreased to 3.4 in two days after withholding warfarin and administering an oral dose of vitamin K. Six days after restarting warfarin at a lower dose (27.5 mg/week vs. 35 to 37.5 mg/week prior to cabozantinib), the patient's INR was measured at 18, with evidence of minor bleeding. Cabozantinib was subsequently discontinued, and the patient's INR returned to target values following resumption of his pre-cabozantinib warfarin dose.<br><br>The mechanism for this reported interaction is unclear. Although cabozantinib has been shown in vitro to inhibit several enzymes involved in warfarin metabolism (eg, CYP2C9, CYP2C19, CYP3A4), in vivo data concerning a purported effect on CYP2C8 have suggested that a clinically relevant effect of cabozantinib on these enzymes in vivo is unlikely.<sup>2,3</sup> It is also possible that this reported interaction represents an indirect effect of cabozantinib, as the patient in the published case reported mouth sensitivity, anorexia, and nausea following initiation of cabozantinib. His total bilirubin also increased during therapy. Decreased vitamin K intake, impaired liver function, and/or other similar consequences of therapy could have contributed to a temporary increase in warfarin sensitivity, at least partially accounting for the observed increases in INR during combination therapy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Foxx-Lupo WT, Sing S, Alwan L, Tykodi SS. A drug interaction between cabozantinib and warfarin in a patient with renal cell carcinoma. <i>Clin Genitourin Cancer</i>. 2016;14(1):e119-121. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26549824\">[PubMed 26549824]</a></p>\n<p>2. Cometriq (cabozantinib) [prescribing information]. South San Francisco, CA: Exelixis, Inc.; May 2016.</p>\n<p>3. Cabometyx (cabozantinib) [prescribing information]. South San Francisco, CA: Exelixis, Inc.; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10469":"<p><b>Title</b> Telithromycin / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Telithromycin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Closely monitor patients taking moderate CYP3A4 inhibitors with telithromycin for evidence of telithromycin adverse effects. Since telithromycin is a strong CYP3A4 inhibitor itself, concurrent use of telthromycin with some specific moderate CYP3A4 inhibitors that are also CYP3A4 substrates are contraindicated or should otherwise be avoided (eg, conivaptan, crizotinib, nilotinib).</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> The telithromycin prescribing information states that co-administration of telithromycin with CYP3A4 inhibitors may result in increases in therapeutic and/or adverse effects.<sup>1</sup> The telithromycin AUC was an average of 54% to 95% higher with concurrent use of the strong CYP3A4 inhibitors itraconazole or ketoconazole.<sup>1,2</sup> Conversely, telithromycin concentrations were not significantly increased with concurrent use of the moderate CYP3A4 inhibitor grapefruit juice in a group of healthy volunteers.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ketek (telithromycin) [prescribing information]. Bridgewater, NJ; Sanofi-Aventis U.S. LLC; October 2015.</p>\n<p>2. Shi J, Montay G, Leroy B, Bhargava VO. Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin. <i>Pharmacotherapy</i>. 2005;25(1):42-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15767219\">[PubMed 15767219]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10483":"<p><b>Title</b> Gallium Ga 68 Dotatate / Somatostatin Analogs</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Somatostatin Analogs may diminish the therapeutic effect of Gallium Ga 68 Dotatate. Specifically, a false negative PET scan may occur if Gallium GA 68 Dotatate is used during treatment with somatostatin analogs. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Imaging with gallium Ga 68 dotatate positron emission tomography (PET) should be performed just prior to dosing with long-acting somatostatin analogs. Short-acting somatostatin analogs can be used up to 24 hours before imaging with gallium Ga 68 dotatate.</p>\n<div>\n <p><b>Somatostatin Analogs Interacting Members</b> Lanreotide, Octreotide, Pasireotide, Somatostatin Acetate</p>\n</div> \n<p><b>Discussion</b> Prescribing information for gallium Ga 68 dotatate states that since somatostatin analogs competitively bind to the same somatostatin receptors as gallium Ga 68 dotatate, concomitant use may prevent the uptake of gallium Ga 68 dotatate into tissues and affect imaging results.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Netspot (gallium Ga 68 dotatate) [prescribing information]. New York, NY: Advanced Accelerator Applications USA Inc; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10484":"<p><b>Title</b> Blood Pressure Lowering Agents / Quinagolide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Quinagolide may enhance the hypotensive effect of Blood Pressure Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs or symptoms of excessive blood pressure reduction. Advise patients of the possible increased risk for symptoms such as dizziness or syncope, and encourage patients to report any evidence of those or other symptoms.</p>\n<div>\n <p><b>Blood Pressure Lowering Agents Interacting Members</b> Acebutolol, Alacepril, Aldesleukin, Aliskiren, Amifostine, AMILoride, Amiodarone, AmLODIPine, Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Amyl Nitrite, Apomorphine, Arotinolol, Arsenic Trioxide, Atenolol, Azilsartan, Barnidipine, Benazepril, Bendroflumethiazide, Benidipine, Bepridil, Betaxolol (Systemic), Bisoprolol, Bortezomib, Bretylium, Bromocriptine, Bumetanide, Bupivacaine, Candesartan, Captopril, Carbetocin, Carvedilol, Celiprolol, Chlorothiazide, ChlorproMAZINE, Chlorthalidone, Cilazapril, Cilnidipine, Clevidipine, Clofarabine, ClomiPRAMINE, CloNIDine, CloZAPine, Conivaptan, Cyclopenthiazide, Desflurane, Dexmedetomidine, DilTIAZem, Dinutuximab, Doxazosin, Efonidipine, Enalapril, Enalaprilat, Eplerenone, Epoprostenol, Eprosartan, Esmolol, Ethacrynic Acid, Felodipine, Fenoldopam, Ferric Gluconate, Fimasartan, Fosinopril, Furosemide, Guanethidine, GuanFACINE, Halothane, HydrALAZINE, HydroCHLOROthiazide, Hydroflumethiazide, Iloprost, Imidapril, Imipramine, Indapamide, Indoramin, Irbesartan, Iron Sucrose, Isocarboxazid, Isoflurane, Isosorbide Dinitrate, Isradipine, Labetalol, Lacidipine, Lercanidipine, Levobupivacaine, Levodopa, Levosimendan, Lisinopril, Lofexidine, Losartan, Manidipine, Mecamylamine, Methyclothiazide, Methyldopa, MetOLazone, Metoprolol, Minoxidil (Systemic), Moexipril, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nabilone, Nadolol, Nebivolol, Nesiritide, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Nitric Oxide, Nitroglycerin, Nitroprusside, Obinutuzumab, Olmesartan, Oxprenolol, PACLitaxel (Conventional), Penbutolol, Pergolide, Perindopril, Phenelzine, Phenoxybenzamine, Phentolamine, Pindolol, Pipamperone [INT], Pramipexole, Prazosin, Promazine, Propofol, Propranolol, Quinapril, Ramipril, Rasagiline, Remifentanil, Reserpine, Rilmenidine, Riociguat, ROPINIRole, Ropivacaine, Rotigotine, Sacubitril, Selegiline, Sevoflurane, Sodium Nitrite, Sotalol, Spironolactone, Streptokinase, SUFentanil, Tamsulosin, Telmisartan, Terazosin, Thalidomide, Thioridazine, Timolol (Systemic), TiZANidine, Tolazoline, Tolcapone, Torsemide, Trandolapril, Tranylcypromine, Tretinoin (Systemic), Triamterene, Valsartan, Verapamil, Xipamide, Zofenopril</p>\n</div> \n<p><b>Discussion</b> The quinagolide product monograph states that the use of quinagolide with antihypertensive agents may result in additional blood pressure-lowering effects.<sup>1</sup> Specific data about such combinations are not available. The frequency of blood pressure-related adverse effects with quinagolide is uncertain, but according to data in the labeling on 549 patients receiving quinagolide for 1 month, more than 10% of patients experienced dizziness, 1.3% experienced hypotension, and 0.9% experienced syncope.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Norprolac (quinagolide) [product monograph]. Toronto, Ontario, Canada: Ferring Inc.; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10485":"<p><b>Title</b> Quinagolide / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Quinagolide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of increased quinagolide adverse effects with any concurrent use of alcohol. Advise patients that the combination may result in decreased tolerability of quinagolide.</p> \n<p><b>Discussion</b> The quinagolide product monograph cautions that the concurrent use of alcohol may result in decreased quinagolide tolerance.<sup>1</sup> Specific data concerning the combination are not provided, and the specific mechanism for the purported interaction is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Norprolac (quinagolide) [product monograph]. Toronto, Ontario, Canada: Ferring Inc.; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10491":"<p><b>Title</b> Cholera Vaccine / Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following use of oral or parenteral antibiotics.</p>\n<div>\n <p><b>Antibiotics Interacting Members</b> Amdinocillin, Amikacin, Amoxicillin, Ampicillin, Arbekacin, Azithromycin (Systemic), Aztreonam (Systemic), Bacampicillin, Bacitracin (Systemic), Bedaquiline, Capreomycin, Cefaclor, Cefadroxil, Cefazedone, CeFAZolin, Cefcapene, Cefdinir, Cefepime, Cefixime, Cefminox, Cefoperazone, Cefotaxime, CefoTEtan, Cefotiam, CefOXitin, Cefpirome, Cefpodoxime, Cefprozil, Ceftaroline Fosamil, CefTAZidime, Ceftezole, Ceftibuten, Ceftizoxime, Ceftobiprole, Ceftolozane, CefTRIAXone, Cefuroxime, Cephalexin, Cephalothin, Cephradine, Chloramphenicol (Ophthalmic), Chloramphenicol (Otic), Chloramphenicol (Systemic), Ciprofloxacin (Systemic), Clarithromycin, Clindamycin (Systemic), Clofazimine, Cloxacillin, Colistimethate, CycloSERINE, Dalbavancin, Dapsone (Systemic), Delafloxacin, Delamanid, Demeclocycline, Dicloxacillin, Doripenem, Doxycycline, Ertapenem, Erythromycin (Systemic), Ethambutol, Ethionamide, Flomoxef, Flucloxacillin, Fosfomycin, Fusidic Acid (Systemic), Gemifloxacin, Gentamicin (Systemic), Imipenem, Isepamicin, Isoniazid, Ivermectin (Systemic), Kanamycin, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lincomycin, Linezolid, Lomefloxacin, Lymecycline, Meropenem, Methenamine, MetroNIDAZOLE (Systemic), Minocycline, Moxifloxacin (Systemic), Nafcillin, Nalidixic Acid, Nifuroxazide, Nitrofurantoin, Norfloxacin, Ofloxacin (Systemic), Oritavancin, Oxacillin, Oxytetracycline, Pefloxacin, Penicillin G (Parenteral/Aqueous), Penicillin G Benzathine, Penicillin G Procaine, Penicillin V Benzathine, Penicillin V Potassium, Pentamidine (Oral Inhalation), Pentamidine (Systemic), Pipemidic Acid, Piperacillin, Polymyxin B, Prothionamide, Pyrazinamide, Rifabutin, RifAMPin, Rifapentine, Roxithromycin, Secnidazole, Silver Sulfadiazine, Sparfloxacin, Spiramycin, Streptomycin, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, Tedizolid, Teicoplanin, Telavancin, Telithromycin, Temocillin, Tetracycline (Systemic), Ticarcillin, Tinidazole, Tobramycin (Systemic), Trimethoprim, Vancomycin<br><b>Exceptions</b> Acetic Acid (Otic), Acetic Acid (Topical), Aluminum Acetate, Azithromycin (Ophthalmic), Aztreonam (Oral Inhalation), Bacitracin (Ophthalmic), Bacitracin (Topical), Benzoin, Chlortetracycline, Ciprofloxacin (Ophthalmic), Clindamycin (Topical), Dapsone (Topical), Dibrompropamidine (Ophthalmic), Dibrompropamidine (Topical), Erythromycin (Ophthalmic), Erythromycin (Topical), Fidaxomicin, Framycetin, Fusidic Acid (Ophthalmic), Fusidic Acid (Topical), Gatifloxacin, Gentamicin (Ophthalmic), Gentamicin (Topical), Gentian Violet, Hexachlorophene, Mafenide, MetroNIDAZOLE (Topical), Mupirocin, Neomycin, Nitrofurazone, Oxychlorosene, Ozenoxacin, Povidone-Iodine (Topical), RifAXIMin, Silver Nitrate, Sulfacetamide (Ophthalmic), Sulfacetamide (Topical), Taurolidine, Tobramycin (Ophthalmic)</p>\n</div> \n<p><b>Discussion</b> US prescribing information for cholera vaccine states that it should not be used during systemic antibiotic treatment because antibiotics may prevent the multiplication of the vaccine strain needed to induce immune response.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vaxchora (cholera vaccine) [prescribing information]. Redwood City, CA: PaxVax Inc; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10492":"<p><b>Title</b> Ajmaline / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Ajmaline. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased ajmaline effects/therapeutic failure if combined with a strong CYP3A4 inducer.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Ajmaline product labeling states that concomitant use of enzyme-inducing drugs (eg, phenytoin, phenobarbital, carbamazepine, rifampin) and ajmaline may result in increased ajmaline metabolism and reduced ajmaline concentrations and effects.<sup>1</sup> <br><br>In contrast, most available data suggests that ajmaline is primarily metabolized by CYP2D6, an enzyme generally considered to be non-inducible.<sup>1,2,3</sup> No study has evaluated the effect of enzyme-inducing drugs on ajmaline exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gilurytmal [summary of product characteristics] Bahnhofstrasse, Germany: Carinopharm GmbH; September 2013.</p>\n<p>2. Koppel C, Tenczer J, Arndt I. Metabolic disposition of ajmaline. <i>Eur J Drug Metab Pharmacokinet</i>. 1989;14(4):309-316. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2633926\">[PubMed 2633926]</a></p>\n<p>3. Hori R, Okumura K, Inui K, et al. Quinidine-induced rise in ajmaline plasma concentrations. <i>J Pharm Pharmacol</i>. 1984;36(3):202-204. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6144760\">[PubMed 6144760]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10493":"<p><b>Title</b> CYP2D6 Substrates (High risk with Inhibitors) / Ajmaline</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ajmaline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased effects and toxicities of CYP2D6 substrates (or decreased effects if the drug is a prodrug activated by CYP2D6) if combined with ajmaline.</p>\n<div>\n <p><b>CYP2D6 Substrates (High risk with Inhibitors) Interacting Members</b> Ajmaline, Amitriptyline, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, AtoMOXetine, Brexpiprazole, Captopril, Carvedilol, Chloroquine, Chlorpheniramine, ChlorproMAZINE, ClomiPRAMINE, Codeine, Dapoxetine, Desipramine, Deutetrabenazine, Dextromethorphan, Doxepin (Systemic), Doxepin (Topical), DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eliglustat, Flecainide, FLUoxetine, FluPHENAZine, FluvoxaMINE, Gefitinib, Haloperidol, Iloperidone, Imipramine, Indoramin, Maprotiline, Mequitazine, Methamphetamine, Metoprolol, Mexiletine, Mirtazapine, Nefazodone, Nortriptyline, Olmutinib, PARoxetine, Perhexiline, Perphenazine, Pimozide, Primaquine, Procainamide, Propafenone, Propranolol, Protriptyline, RisperiDONE, Syrian Rue, Tamoxifen, Tetrabenazine, Thioridazine, Timolol (Ophthalmic), Timolol (Systemic), Tolterodine, Trimipramine, Tropisetron, Venlafaxine, Vortioxetine, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Ajmaline product labeling states that concomitant use of CYP2D6 substrates and ajmaline may lead to significant increases in CYP2D6 substrate exposure.<sup>1</sup> In vitro data indicate that ajmaline may inhibit CYP2D6, but no human studies have been conducted to assess the potential for ajmaline to increase serum concentrations of CYP2D6 substrates in humans.<sup>2</sup> Monitoring for increased effects and toxicities of CYP2D6 substrates is recommended, particularly when using a continuous intravenous infusion of ajmaline.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gilurytmal [summary of product characteristics] Bahnhofstrasse, Germany: Carinopharm GmbH; September 2013.</p>\n<p>2. Broly F, Libersa C, Lhermitte M, Dupuis B. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. <i>Biochem Pharmacol</i>. 1990;39(6):1045-1053. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2322292\">[PubMed 2322292]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10494":"<p><b>Title</b> Ajmaline / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase the serum concentration of Ajmaline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased ajmaline effects and toxicities if combined with strong CYP2D6 inhibitors.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 4 healthy volunteers, the strong CYP2D6 inhibitor quinidine (100 mg x 1 followed by 200 mg x1 12 hours later) increased the ajmaline (50 mg single dose) AUC and maximum serum concentration 22-fold and 7.8-fold, respectively.<sup>1</sup><br><br>Ajmaline product labeling states that because ajmaline is metabolized by CYP2D6, concomitant use with CYP2D6 inhibitors may increase ajmaline concentrations and effects.<sup>2</sup><br><br>Although not fully investigated, the likely mechanism of this interaction is inhibition of CYP2D6, an enzyme responsible for ajmaline metabolism.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hori R, Okumura K, Inui K, et al. Quinidine-induced rise in ajmaline plasma concentrations. <i>J Pharm Pharmacol</i>. 1984;36(3):202-204. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6144760\">[PubMed 6144760]</a></p>\n<p>2. Gilurytmal [summary of product characteristics] Bahnhofstrasse, Germany: Carinopharm GmbH; September 2013.</p>\n<p>3. Koppel C, Tenczer J, Arndt I. Metabolic disposition of ajmaline. <i>Eur J Drug Metab Pharmacokinet</i>. 1989;14(4):309-316. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2633926\">[PubMed 2633926]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10495":"<p><b>Title</b> Ajmaline / Sulfonamides</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of cholestasis (eg, jaundice, elevated alkaline phosphatase) if ajmaline is combined with sulfonamides.</p>\n<div>\n <p><b>Sulfonamides Interacting Members</b> AcetaZOLAMIDE, Bendroflumethiazide, Bumetanide, Celecoxib, Chlorothiazide, ChlorproPAMIDE, Chlorthalidone, Cyclopenthiazide, Furosemide, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Nimesulide, Parecoxib, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, Sulfanilamide, SulfiSOXAZOLE, Sulthiame, TOLAZamide, TOLBUTamide, Torsemide, Xipamide</p>\n</div> \n<p><b>Discussion</b> One case report describes a 52-year-old woman who experienced prolonged intrahepatic cholestasis after being treated with ajmaline and the methyltestosterone/ethinyl estradiol combination product.<sup>1</sup> <br><br>Ajmaline product labeling states that since ajmaline has been associated with cholestasis, concomitant use with other medications that also cause cholestasis may result in an increased incidence and a more prolonged course of cholestasis.<sup>2</sup> Medications specifically listed that may increase this cholestasis risk include hormones (ie, estrogens, androgens), sulfonamides, salicylates, and diazepam.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Beermann B, Ericsson JL, Hellstrom K, Wengle B, Werner B. Transient cholestasis during treatment with ajmaline, and chronic xanthomatous cholestasis after administration of ajmaline, methyltestosterone and ethinylestradiol. Two case reports. <i>Acta Med Scand</i>. 1971;190(4):241-250. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5124256\">[PubMed 5124256]</a></p>\n<p>2. Gilurytmal [summary of product characteristics] Bahnhofstrasse, Germany: Carinopharm GmbH; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10496":"<p><b>Title</b> Ajmaline / Salicylates</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Salicylates may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of cholestasis (eg, jaundice, elevated alkaline phosphatase) if ajmaline is combined with salicylates.</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n</div> \n<p><b>Discussion</b> One case report describes a 52-year-old woman who experienced prolonged intrahepatic cholestasis after being treated with ajmaline and the methyltestosterone/ethinyl estradiol combination product.<sup>1</sup> <br><br>Ajmaline product labeling states that since ajmaline has been associated with cholestasis, concomitant use with other medications that also cause cholestasis may result in an increased incidence and a more prolonged course of cholestasis.<sup>2</sup> Medications specifically listed that may increase this cholestasis risk include hormones (ie, estrogens, androgens), sulfonamides, salicylates, and diazepam.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Beermann B, Ericsson JL, Hellstrom K, Wengle B, Werner B. Transient cholestasis during treatment with ajmaline, and chronic xanthomatous cholestasis after administration of ajmaline, methyltestosterone and ethinylestradiol. Two case reports. <i>Acta Med Scand</i>. 1971;190(4):241-250. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5124256\">[PubMed 5124256]</a></p>\n<p>2. Gilurytmal [summary of product characteristics] Bahnhofstrasse, Germany: Carinopharm GmbH; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10497":"<p><b>Title</b> Ajmaline / DiazePAM</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> DiazePAM may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of cholestasis (eg, jaundice, elevated alkaline phosphatase) if ajmaline is combined with diazepam.</p> \n<p><b>Discussion</b> One case report describes a 52-year-old woman who experienced prolonged intrahepatic cholestasis after being treated with ajmaline and the methyltestosterone/ethinyl estradiol combination product.<sup>1</sup> <br><br>Ajmaline product labeling states that since ajmaline has been associated with cholestasis, concomitant use with other medications that also cause cholestasis may result in an increased incidence and a more prolonged course of cholestasis.<sup>2</sup> Medications specifically listed that may increase this cholestasis risk include hormones (ie, estrogens, androgens), sulfonamides, salicylates, and diazepam.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Beermann B, Ericsson JL, Hellstrom K, Wengle B, Werner B. Transient cholestasis during treatment with ajmaline, and chronic xanthomatous cholestasis after administration of ajmaline, methyltestosterone and ethinylestradiol. Two case reports. <i>Acta Med Scand</i>. 1971;190(4):241-250. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5124256\">[PubMed 5124256]</a></p>\n<p>2. Gilurytmal [summary of product characteristics] Bahnhofstrasse, Germany: Carinopharm GmbH; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10498":"<p><b>Title</b> Ajmaline / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of cholestasis (eg, jaundice, elevated alkaline phosphatase) if ajmaline is combined with estrogen derivatives.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> One case report describes a 52-year-old woman who experienced prolonged intrahepatic cholestasis after being treated with ajmaline and the methyltestosterone/ethinyl estradiol combination product.<sup>1</sup> <br><br>Ajmaline product labeling states that since ajmaline has been associated with cholestasis, concomitant use with other medications that also cause cholestasis may result in an increased incidence and a more prolonged course of cholestasis.<sup>2</sup> Medications specifically listed that may increase this cholestasis risk include hormones (ie, estrogens, androgens), sulfonamides, salicylates, and diazepam.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Beermann B, Ericsson JL, Hellstrom K, Wengle B, Werner B. Transient cholestasis during treatment with ajmaline, and chronic xanthomatous cholestasis after administration of ajmaline, methyltestosterone and ethinylestradiol. Two case reports. <i>Acta Med Scand</i>. 1971;190(4):241-250. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5124256\">[PubMed 5124256]</a></p>\n<p>2. Gilurytmal [summary of product characteristics] Bahnhofstrasse, Germany: Carinopharm GmbH; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10499":"<p><b>Title</b> Ajmaline / Androgens</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Androgens may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of cholestasis (eg, jaundice, elevated alkaline phosphatase) if ajmaline is combined with androgens.</p>\n<div>\n <p><b>Androgens Interacting Members</b> Danazol, Fluoxymesterone, Mesterolone, MethylTESTOSTERone, Nandrolone, Oxandrolone, Oxymetholone, Testosterone</p>\n</div> \n<p><b>Discussion</b> One case report describes a 52-year-old woman who experienced prolonged intrahepatic cholestasis after being treated with ajmaline and the methyltestosterone/ethinyl estradiol combination product.<sup>1</sup> <br><br>Ajmaline product labeling states that since ajmaline has been associated with cholestasis, concomitant use with other medications that also cause cholestasis may result in an increased incidence and a more prolonged course of cholestasis.<sup>2</sup> Medications specifically listed that may increase this cholestasis risk include hormones (ie, estrogens, androgens), sulfonamides, salicylates, and diazepam.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Beermann B, Ericsson JL, Hellstrom K, Wengle B, Werner B. Transient cholestasis during treatment with ajmaline, and chronic xanthomatous cholestasis after administration of ajmaline, methyltestosterone and ethinylestradiol. Two case reports. <i>Acta Med Scand</i>. 1971;190(4):241-250. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5124256\">[PubMed 5124256]</a></p>\n<p>2. Gilurytmal [summary of product characteristics] Bahnhofstrasse, Germany: Carinopharm GmbH; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}